Revenue Grows 13% to $66.9 Million in Fiscal 2024, Marking Strong Year-Over-Year Growth
Cemtrex Highlights $1.3 Million in Notable New Contracts in Past Week Across Security and Industrial Divisions, Reinforces FY26 Growth Outlook
Cemtrex continues to secure high-value contracts, including a $10.4 million order for Valerus surveillance systems and a $1.2 million order for border security technology, showcasing the company’s growing traction in critical sectors.
Our profiles from Tuesday and Wednesday both saw significant double digit moves.
We will keep you updated about Thursday’s profile.
Now you want to take a look at CETX.
This one is sitting around 1.30 which is right in that sweet spot we like to look at companies.
Don’t take off for the weekend just yet. We want you to put CETX on your screen for Friday’s session.
Cemtrex, Inc. (Nasdaq: CETX) is a diversified technology company operating in the Security and Industrial sectors. Its Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure. The Industrial segment, through Advanced Industrial Services (AIS), delivers expert rigging, mill-wrighting, process piping, and equipment installation services to manufacturers nationwide. With a focus on innovation, execution, and strategic growth, Cemtrex is committed to enhancing safety, efficiency, and value for its customers and shareholders.
The next company that we want you to turn your attention to is ticker CETX.
In today’s rapidly evolving landscape, industries face increasing challenges in securing critical infrastructure and maintaining operational efficiency. Traditional security systems are struggling to keep up with modern threats, while industrial sectors require advanced, cost-effective solutions to meet growing demands.
The market lacks comprehensive, scalable security systems that integrate AI-driven analytics and seamless cloud-based platforms. Simultaneously, industrial services providers need robust, reliable solutions for complex infrastructure projects that can be delivered with speed and precision.
Cemtrex, Inc. (NASDAQ:CETX) recognizes these gaps, offering cutting-edge, customizable security solutions and industrial services designed to enhance safety, operational effectiveness, and scalability across diverse sectors, providing much-needed innovation in critical markets.
Empowering Growth Through Two Dynamic Subsidiaries: Vicon Industries and Advanced Industrial Services (AIS)
Cemtrex Inc. (NASDAQ: CETX) is at the forefront of redefining the future of security and industrial services. Through its two key subsidiaries[vi] — Vicon Industries and Advanced Industrial Services (AIS) — Cemtrex is driving growth and innovation in rapidly expanding markets.
With the increasing global demand for smart security solutions and industrial services, Cemtrex is positioned to capture significant market share. The company’s strategic investments in AI-driven security systems and advanced industrial services are setting the stage for long-term success.
Cemtrex is committed to delivering value to its shareholders by capitalizing on market demand, executing strategic initiatives, and scaling its operations effectively. The company’s innovative products and services are key to unlocking new opportunities and sustaining growth.
As the market continues to evolve, Cemtrex is well-placed to lead with its cutting-edge solutions, unlocking substantial growth potential in the years ahead.
Their technology is impressive.
Check out this video:
CETX just released a shareholder update on the 1st of this month. Here are some of the key points:
Vicon: Momentum, Execution, and the Launch of NEXT
Vicon, our intelligent security division, is performing. Since 2021, we’ve grown revenue from $21 million to a projected $36 million-plus for fiscal year 2025. Gross margins have improved, and our go-to-market engine is accelerating, fueled by the addition of over 60 new resellers this year alone.
Our new modular camera platform, NEXT, began shipping this quarter. It’s our most advanced product line to date—fast to install, AI-powered, visually modern, and designed to meet the complex needs of today’s enterprise and public infrastructure buyers. Early wins, including a $500K school district deployment, are encouraging. We believe this platform has the potential to become the core of Vicon’s next growth phase.
This year, Vicon has delivered:
$1.2M U.S. county security project
$1.2M U.S. border security contract
$1M international deployment in Saudi Arabia
$800K system for a UK prison facility
$10.4M contract in December 2024—the largest in our history
These are not pipeline projections—they’re closed deals. Vicon is performing in the market, and we are scaling it with intention.
AIS: Durable Growth with Strategic Ambition
AIS has quietly doubled in size since 2021, with revenue on track to exceed $36 million this year. Demand from food and beverage, packaging, and machinery sectors remains strong, and reshoring trends are creating more opportunity for our services.
We are no longer just a millwright and installation business. We are positioning AIS to become a full-spectrum industrial services platform, one that can handle legacy systems and lead the transition to automated, robotics-enabled manufacturing environments.
To that end, we are in advanced discussions to acquire a Midwest-based robotics integrator. This deal, if completed, would expand our capabilities into robotic workcell design, controls programming, and systems integration, allowing us to better serve manufacturers modernizing their facilities.
Our M&A playbook is disciplined. Our last acquisition was accretive, smoothly integrated, and strengthened our platform. We expect the same results as we scale.
Solana and Blockchain Infrastructure
In July, we allocated $1 million into Solana (SOL) and have since staked our holdings. We view Solana as one of the most structurally sound blockchains in production—high throughput, low latency, and deflationary mechanics hardcoded into the protocol.
This is not a hedge. It’s a strategic bet.
Blockchain infrastructure will become critical to how digital systems establish truth. Whether it’s timestamping surveillance footage, detecting tampering in AI-generated content, or anchoring public safety evidence in immutable ledgers—we believe this technology will be foundational.
Vicon has already begun R&D around blockchain-based video authentication. We intend to move quickly.
Vicon shift to AI Based Analytics solutions & Cloud based VSaaS to drive recurring revenue growth in high gross margin businesses Security segment revenues decreased 7% to $32.0M in FY’24 due to the delay of multiple projects for the segment’s products and services.
CATALYSTS:
AIS set to expand with strong growth in the Industrial Services market AIS segment revenues increased 39% to $34.8M in FY’24
Generating margin improvement through increasing prices and reducing overhead where possible Gross margin was 41% in FY’24
Subsequently announced a $10.4 million Valerus expansion order from a state government corrections customer and three contracts for AIS totaling $11.4 million
M&A strategy targeting acquisitions in high growth markets with strong ROE and attractive gross margins
Large, growing, addressable and mature markets in Security, Business, Manufacturing, Government & Industrial
Revenue for the year ended September 30, 2024, increased 13% to $66.9 million, compared to revenue in the prior year of $59.4 million.
Revenue for Q4’24 increased 9% to $18.1 million, compared to revenue of $16.6 million for Q4’23.
Vicon Innovations: Launched NEXT™ Modular Camera System, integrating groundbreaking AI analytics and Hailo-15 edge AI processing, poised to redefine the surveillance industry.
Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve
Hauppauge, NY, July 31, 2025 (GLOBE NEWSWIRE) — Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security systems and industrial services, today announced it has acquired approximately $1 million worth of Solana (SOL) as part of a new digital asset treasury strategy, with the goal of expanding its crypto reserves to $10 million over time.
“Solana is the most underappreciated layer-one blockchain in the world today,” said Saagar Govil, Chairman and CEO of Cemtrex. “It’s already processing more real-world transactions than every other blockchain combined, and it’s not even close. With a hard-coded supply curve and no reliance on fragmented scaling solutions, we believe the market has yet to appreciate what this unlocks in the next 3–5 years.”
Cemtrex purchased 5,500 SOL at an average cost of approximately $181 per token. The company intends to stake its position for on-chain yield and eventually operate its own validator node to directly participate in network security and infrastructure. Cemtrex’s longer term goal is to build a $10 million reserve position across strategic crypto networks, with Solana as the foundation.
Solana is currently processing over 1,000 transactions per second and handled more than 90 billion transactions in June 2025 alone, more than every other L1 and L2 combined. With a burn mechanism tied to usage and a hardcoded inflation schedule set to bottom out at 1.5% by 2028, we believe Solana is uniquely positioned to become a foundational layer for digital trust and settlement.
“This isn’t just a treasury hedge,” Govil added. “It’s a long-duration bet on the most capable, capital-efficient blockchain system in production and one we believe will compound its network advantage faster than the market expects. Over time, we expect Solana to outperform fiat and legacy digital assets on a structural basis.”
Cemtrex is actively exploring ways to integrate blockchain-based technologies into its product lines, including cryptographic video authentication, tamper-proof media verification, and decentralized timestamping through its subsidiary, Vicon.
“This is a long-term strategy grounded in execution. We’re putting capital and infrastructure behind it because we see where this is going,” continued Govil.
Cemtrex’s Vicon Secures $1.2M Follow-On Order for County Security Infrastructure Expansion
Repeat order from major government project highlights accelerating public-sector adoption of Vicon’s video surveillance solutions
Hauppauge, NY, July 08, 2025 (GLOBE NEWSWIRE) — Vicon Industries, a subsidiary of Cemtrex Inc. (Nasdaq: CETX, CETXP) and a leading provider of advanced security and surveillance solutions, today announced that it has secured a follow-on order exceeding $1.2 million to support a major Midwestern county government security upgrade project. The order was placed through a long-standing global systems integration partner.
The scope of the project includes Vicon’s high-performance cameras, recording servers, and Valerus video management software licenses, all deployed to enhance security across multiple county facilities. This order builds on previous deployments and reflects continued customer confidence in Vicon’s reliability, scalability, and system performance. The order is expected to be fulfilled over the coming months and contribute to Vicon’s fiscal 2025 results. Consistent with the terms of the engagement, the names of the client and integration partner are not being disclosed.
“This award reflects the strength of our execution and the trust we’ve earned with key public-sector stakeholders,” said Saagar Govil, Chairman and CEO of Cemtrex. “As municipalities invest in more advanced and unified security platforms, Vicon is increasingly the partner of choice.”
This engagement marks one of Vicon’s largest public-sector wins in recent quarters and reinforces a broader pattern of repeat institutional orders, particularly in government and education verticals. While this deployment leverages Vicon’s established product lines, it comes amid growing market interest in the company’s next-generation offerings, including the award-winning NEXT Modular Sensor System, which has recently been recognized for innovation and design excellence.
“We’re seeing an encouraging pattern take hold,” Govil added. “This order is not an isolated event, it reflects growing momentum from institutional buyers who’ve deployed our systems, seen the results, and are investing further. With an expanding base of repeat government customers, visibility into our long-term growth is becoming clearer.”
Strategic Outlook
This order is further validation of Cemtrex’s ongoing strategy of transforming Vicon from a legacy camera business into a modern surveillance technology platform. The Company’s emphasis on modular design, AI-enhanced analytics, and public-sector readiness is translating into real-world traction, and into contracts with repeat customers executing multi-year infrastructure upgrades.
“We’ve spent the past several years repositioning Vicon for long-term success, and orders like this reflect that transformation taking hold,” said Govil. “We’re executing against a clear strategy, focused on delivering differentiated solutions to institutional customers, and the results are starting to materialize across our pipeline.”
Following recent industry awards, increased sales velocity, and a growing pipeline of institutional projects, Vicon is positioned to deliver meaningful year-over-year growth in fiscal 2025 and beyond.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND ONE HUNDRED SEVENTY FIVE USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY CETX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback
Some of the company’s high-potential mineral rights are adjacent to or near large lithium deposits that belong to a large, publicly traded comparable that boasts a $1.2 Billion market cap!
Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries
Atlas Critical Minerals (OTCQB: JUPGF) reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6%… pic.twitter.com/9Wzc7A4u2i
— Atlas Lithium (Nasdaq: ATLX) (@Atlas_Lithium) July 24, 2025
_________________________
Hello Everyone,
I hope that you were paying attention to Tuesday’s intense crypto profile that has been super volatile the past few weeks on the back of strong news.
It closed Tuesday 23.56. It just hit 31.62 during Wednesday’s session.
That one was a little higher priced than the companies we have been taking a look at as of late.
Moving on we want you to take another look at ATLX. You should be familiar with this one.
We just brought it to your attention last month when it traded as low as 4.60. Just 7 sessions later it tapped 7 bucks on way above average interest.
Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.
ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.
The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.
Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.
ATLX holds three key projects that span the major lithium-mineralized zones in LV:
The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;
The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;
The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)
Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback
Boca Raton, Florida–(Newsfile Corp. – August 4, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company, is pleased to announce that SGS Canada Inc. (“SGS”) has completed the Definitive Feasibility Study (“DFS”) for the Company’s 100%-owned Neves Lithium Project (“Project”), a technical report prepared under the U.S. guidelines of Item 1300 of Regulation S-K (“Regulation S-K 1300”). This hard-rock Project is well-suited to being a low-cost open-pit mining operation, as its spodumene deposits are located relatively close to the surface. Located in the state of Minas Gerais, Brazil, the Project encompasses 4 of the 98 mineral rights for lithium owned by Atlas Lithium. As detailed in the DFS, the Neves Project is expected to deliver strong financial metrics with an internal rate of return (“IRR”) of 145%, payback in 11 months from the start of operations, and an after-tax net present value (“NPV”) of $539 million. Importantly, the DFS estimates the Neves Project to have operational production costs of only $489 per tonne of lithium concentrate, positioning Atlas Lithium among the world’s lowest-cost producers. Complete details of these metrics can be found in the DFS, filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Marc-Antoine Laporte from SGS serves as the Qualified Person for the DFS under Regulation S-K 1300. SGS is well-known as a global leader in testing, inspection, and certification services for mineral properties and projects.
Industry-Leading Capital Efficiency and Low Operating Costs
The DFS supports that expected direct capital expenditures of $57.6 million will be needed for the implementation of the Project, by far the lowest such capital costs among other announced projects in Brazil. Notably, Atlas Lithium has already invested approximately $30 million in acquiring and transporting the Project’s newly fabricated dense media separation (“DMS”) plant to Brazil, as previously reported. The Company has secured two non-dilutive pre-payment agreements for its lithium concentrate totaling $40 million and has received additional funding interest from other parties, including 10-year debt financing options, any of which could support the Project’s capital requirements.
The Company believes that the DFS validates the Project’s strong economics, positioning it among the most capital-efficient and lowest-cost hard-rock lithium developments globally. The Project will employ proven DMS technology, with comprehensive metallurgical testing demonstrating an expected robust lithium recovery rate of 61.7% to produce high-quality, low-impurity lithium concentrate. This relatively straightforward, low-risk DMS processing methodology minimizes technical complexity and operational risk while enabling a low environmental footprint.
Atlas Lithium’s mineral right to be mined, as detailed in the DFS, received its “Portaria de Lavra” (mining concession) status from Brazil’s Ministry of Mines and Energy on May 27, 2025 — the highest level of titleship in Brazil and one that allows continuous mining operations. Multiple deposit areas within the Project remain open for resource expansion along strike and at depth and are thus expected to extend the life of mine. Additionally, numerous high-potential geological targets remain within the Project’s mineral rights, providing compelling opportunities for future exploration.
Located in the established Araçuaí Pegmatite District in the Vale do Jequitinhonha, often called Lithium Valley, the Project benefits from favorable infrastructure, including proximity to transportation networks, water resources, and skilled labor. The Project qualifies for tax incentives from the Superintendency for the Development of the Northeast (SUDENE), as promulgated by Brazil’s Ministry of Integration and Regional Development, reducing the corporate tax rate from 34% to 15.25% and further enhancing profitability.
“The DFS indicates potentially outstanding returns for our initial vision of developing a focused, near-term, profitable lithium production asset with minimal capital requirements,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “The combination of our low capital intensity and rapid payback period is expected to create exceptional value for our shareholders while positioning Atlas Lithium to benefit from future organic expansion opportunities at Neves and other high-potential lithium areas that we own. Importantly, we are creating many quality employment opportunities in the Vale do Jequitinhonha region, representing a significant societal contribution of our Project.”
Following his leadership role in collaborating with SGS on the DFS, project implementation activities are being supervised by Eduardo Queiroz, Atlas Lithium’s Project Management Officer (PMO) and Vice President of Engineering. Mr. Queiroz has more than two decades of hands-on experience managing complex, large-scale mining projects.
“The DFS demonstrates the technical robustness of the Project, with proven DMS technology and comprehensive metallurgical test work validated by SGS, a premier firm in the lithium space,” said Mr. Queiroz. “With our processing plant fully fabricated and paid for, and now with the DFS in hand, we have systematically de-risked the Project. I am excited to lead the implementation phase of Atlas Lithium’s journey to becoming a lithium producer.”
Salinas and Clear: The Next Expansion Frontier
Atlas Lithium is strategically positioned to capitalize on its extensive regional lithium exploration portfolio in Brazil, particularly through advancement of its Salinas Project and Clear Project, both 100% owned by the Company. Atlas Lithium’s Salinas Project is just 5 miles east of the Colina lithium asset previously owned by Latin Resources — a major factor in Pilbara Minerals’s acquisition of that company in 2024 for approximately $370 million. At the Salinas Project, Atlas Lithium has already achieved promising initial results, including the discovery of spodumene-rich pegmatites very close to the surface, and highly positive results from soil geochemistry and from LIDAR geological mapping.
Atlas Lithium’s Clear Project is located less than 4 miles from Sigma Lithium’s operating lithium mine, and represents significant untapped potential with highly positive results from soil geochemistry and from LIDAR geological mapping.
Diversification in Critical Minerals
Atlas Lithium also owns approximately 30% of Atlas Critical Minerals Corporation (OTCQB: JUPGF), a separate company with exploration programs in uranium, rare earths, titanium, and graphite.
Atlas Critical Minerals reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6% graphite concentrate
Boca Raton, Florida–(Newsfile Corp. – July 24, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or the “Company”), a leading lithium exploration and development company, today announced strong results from its 30.1%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF). The subsidiary has recently reported near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂, alongside graphite concentrate results of up to 96.6%. Atlas Critical Minerals owns over 575,000+ acres of mineral rights for rare earths, titanium, graphite, uranium, copper, and nickel. Brazil, where the subsidiary operates, hosts significant rare earth deposits and holds the world’s second-largest graphite reserves.
Alto Paranaíba Rare Earths and Titanium Project Demonstrates High Potential
Atlas Critical Minerals’ Alto Paranaíba rare earths and titanium project in Minas Gerais, located in a proven rare earths region, is divided into three exploration blocks for operational efficiency as shown in Figure 1.
Atlas Critical Minerals’ 770 surface samples yielded consistently attractive grades, including a sample with 28,870 ppm total rare earth oxides (TREO) and another containing 23.2% titanium dioxide (TiO₂). Highlight sampling results from Block 3 South are presented in Figure 2.
Atlas Critical Minerals’ Minas Gerais graphite project achieved strong metallurgical test results, with conventional flotation techniques producing graphite concentrates grading up to 96.6% total graphite carbon. Exploration samples showed graphite carbon grades up to 15.42%.
Strategic Importance
The strategic importance of securing robust critical minerals supply chains was recently underscored by the U.S. Department of Defense’s $400 million investment in MP Materials, making it the largest shareholder in the U.S. rare earth miner.
Atlas Lithium’s strategic stake in Atlas Critical Minerals provides shareholders with direct exposure to the broader critical minerals sector and strengthens the Company’s position within global supply chains for materials vital to energy transition and national security.
“Our focus remains on advancing our flagship Neves lithium project toward production, while our significant stake in Atlas Critical Minerals allows our shareholders to also benefit from exposure to a broader range of critical minerals at a time of heightened geopolitical importance,” said Marc Fogassa, Chief Executive Officer and Chairman of Atlas Lithium. “The initial results from Atlas Critical Minerals’ rare earths, titanium, and graphite programs are highly encouraging and underscore the strong potential of these assets.”
Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production
Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.
The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.
“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”
Cutting-Edge Modular Plant Design
Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:
Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.
Strategic Progress Toward Production
The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.
Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.
Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure
Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.
“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”
Rare Earths: Essential for Defense, Energy, and High-Tech Applications
Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.
Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.
Graphite: A Cornerstone of Battery Technology
Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.
Uranium: Fueling the Energy Transition
Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.
A Diversified Strategy for a Changing World
Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.
“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”
Strategic Partnership with Global Industrial Giant
In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.
Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.
Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.
“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.
Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.
ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.
Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!
This is a Highly Attractive Location:
◼ Resource Potential to Support Large Scale Operations ✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits ✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL
◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place ✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly ✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais
◼ Favorable Infrastructure ✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets
Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.
A Big Neighbor
Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.
Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.
Tiago Miranda
CFO & Treasurer
Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.
Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.
From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.
From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.
Eduardo Queiroz
Project Management Officer (PMO) & Vice President of Engineering
Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.
Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.
Igor Tkachenko
Vice President, Corporate Strategy
Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FOUR HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
***Sponsored by LFG Equities Corp and Disseminated on Behalf of Cardiol Therapeutics Inc
The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Based on short-term price targets offered by four analysts, the average USD price target for Cardiol Therapeutics Inc. comes to $9.00.
We had a big week last week with some huge winners. There is no doubt the market is heating up, that is if it ever slowed down in the first place.
This next one is hovering right around that all-mighty and critical $1 level. Right in our Sweet-Spot. This company was just over $1.50 less than 2 weeks ago, creating an environment for a potential bounce like we have seen so many times in the past with similar setups.
There is no doubt that massive strides are underway in the cardiovascular space, focusing on therapies for inflammatory heart conditions. These are areas with limited treatment options and a lot of room for advancement and research.
This company just had topline results just drop last week and multiple analyst targets are pointing to triple-digit potential upside. This virtually unknown Nasdaq company should be on your watch list as we head into Wednesday’s open.
Pull up CRDL right away.
Advanced research into rare conditions like pericarditis and myocarditis has begun to yield promising data, with clinical programs advancing towards a potential solution to help patients with underserved heart diseases.
Behind these developments is a dedicated life sciences company guided by experienced leadership and a commitment to addressing some of the most pressing challenges in heart health.
With an ongoing pericarditis trial recruiting participants, recently unveiled myocarditis trial topline data, and a heart failure therapy approaching clinical development, this makes for an important story for those following transformative healthcare innovation.
CRDL is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (“US FDA”) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis.
The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The completed ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure, a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Pericarditis
Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States; following an initial episode, 15 – 30% of patients experience a recurrence.
Pericarditis refers to inflammation of the membrane or sac that surrounds the heart (the pericardium) that is most frequently triggered from a viral infection. Recurrent pericarditis is the most common complication following an initial acute episode of pericarditis, and patients may have multiple recurrences.
Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Infrequent but life-threatening complications associated with pericarditis include a large accumulation of pericardial fluid, scarring, and constriction of the heart which may limit heart function. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.
Cardiol’s MAVERIC program for recurrent pericarditis has two parts. The first, a Phase II study, is already completed. The second, a larger pivotal Phase III trial, is enrolling patients. This global study will show if CardiolRx™ can stop the disease from coming back in high-risk patients and help get it approved by regulators.
Myocarditis
Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is when the heart muscle gets inflamed. It can cause chest pain, trouble with how the heart works, and abnormal heart rhythms. In some cases, it can lead to severe heart failure or even sudden death, especially in people under 35.
Most often, it’s caused by a virus, but it can also come from bacteria, certain medications, mRNA vaccines, or cancer treatments like chemotherapy and immune-based drugs.
CardiolRx™ was tested in the ARCHER trial, a Phase II study which took place in the US, Canada, Brazil, France, and Israel. The goal was to see if the drug is safe, well tolerated, and helps the heart recover in people with acute myocarditis. The topline results were just announced!
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.
Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.
The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.
The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.
Toronto, Ontario – (August 6, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company“), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis. In the two primary endpoints—extracellular volume (“ECV”) and global longitudinal strain (“GLS”)—CardiolRx™ showed a notable improvement in ECV (p = 0.0538) compared to placebo following 12 weeks of double-blind therapy, with no significant difference observed in GLS in a population that had preserved left ventricular (“LV”) function at baseline. The reduction in ECV was associated with improvements over placebo in multiple pre-specified cardiac magnetic resonance imaging (“CMR”) endpoints, including a significant reduction in LV mass. The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis. Consistent with findings from Cardiol’s Phase II MAvERIC trial in recurrent pericarditis, CardiolRx™ was shown to be safe and well tolerated. The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.
“On behalf of the ARCHER Steering Committee, I would like to extend our sincere gratitude to the patients who participated in the study; to their families and caregivers for their invaluable support; and to the clinical trial site investigators and staff, members of the international Steering Committee, and the Data and Safety Monitoring Committee, whose exemplary efforts in patient recruitment, clinical care, trial execution, monitoring, and oversight were instrumental in achieving the compelling findings of the ARCHER trial,” said Dr. Dennis M. McNamara, Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center, and Chair of the ARCHER Steering Committee. “I commend Cardiol for undertaking this important trial that investigated the biological effects of pharmaceutically manufactured cannabidiol in acute myocarditis. The results offer exciting new insights into the treatment of acute myocarditis and strongly support advancing the clinical development of this novel therapeutic approach for inflammatory cardiac conditions, including myocarditis and heart failure. I look forward to collaborating with my colleagues on the Steering Committee as we prepare for the presentation and publication of the comprehensive ARCHER trial data.”
Dr. Leslie T. Cooper, Jr., the Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine at the Mayo Clinic in Jacksonville, Florida, and Co-Chair of the Steering Committee for the ARCHER trial, added, “ARCHER was an important, well-designed, and well-executed clinical trial. The intriguing findings reinforce our original hypothesis that pharmaceutically manufactured cannabidiol can attenuate myocardial inflammation and edema. ARCHER’s results provide sound rationale for advancing the clinical development of this novel therapy in conditions of the myocardium characterized by edema, fibrosis, and remodeling, including the growing challenge of immune checkpoint inhibitor-induced myocarditis which can be fatal.”
“We are delighted with the ARCHER trial results,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “We initiated this ambitious study—focused on a potentially life-threatening cardiac disorder for which there is no established standard of care—to further investigate the therapeutic potential of CardiolRx in inflammatory heart disease. We are thrilled to observe improvements in multiple CMR measures associated with diagnosis, prognosis, and clinical outcomes. As we continue to advance our lead clinical program, the pivotal Phase III MAVERIC trial in recurrent pericarditis, we now look forward to integrating the ARCHER findings into our broader clinical development strategy and business development initiatives—supporting the continued advancement of CardiolRx and CRD-38 as potential treatments for inflammatory cardiac disorders.”
ARCHER is a Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx™ on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal ESC Heart Failure. The study enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel. The two primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac magnetic resonance imaging parameters: extra-cellular volume and global longitudinal strain, which assess myocardial function and tissue characteristics associated with fibrosis and inflammation.
Heart Failure
Heart failure affects more than 64 million people globally and associated healthcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is when the heart can’t pump enough blood and oxygen for the body. This can cause shortness of breath, a fast heartbeat, swelling, low energy, and trouble doing everyday activities. Many people with heart failure end up in the hospital often, and it can greatly affect quality of life.
It can be caused by heart attacks, high blood pressure, heart valve problems, heart inflammation (like myocarditis), certain cancer treatments, or inherited conditions.
CRD-38 is Cardiol’s new subcutaneously administered drug formulation for heart failure. They’re doing the prep work needed before starting clinical trials to see if it can become a new treatment option.
—–
Product Pipeline
Therapeutic Development – CardiolRx™
CardiolRx™ is an oral treatment in development for serious rare heart diseases. It works by blocking several inflammation pathways, including the NLRP3 inflammasome, a key driver of the inflammation and scarring seen in pericarditis, myocarditis, and heart failure.
The drug is made to the highest pharmaceutical standards (cGMP) to ensure purity, consistency, and stability. In clinical trials, CardiolRx™ continues to show a profile that is safe and well tolerated.
These strong safety results helped Cardiol win FDA approvals to run Phase II and Phase III trials in rare heart conditions — recurrent pericarditis and acute myocarditis — giving the company a direct path toward targeting high-value, underserved markets.
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis.
Based on short-term price targets offered by four analysts, the average USD price target for Cardiol Therapeutics Inc. comes to $9.00. The forecasts range from a low of USD$8.00 to a high of USD$10.00.
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.
Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.
Data from Cardiol’s Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx™ experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.
Recurrent pericarditis is a debilitating heart condition that results in chest pain, shortness of breath and fatigue, physical limitations, reduced quality of life, and hospitalizations.
CardiolRx™, which has been granted US FDA Orphan Drug Designation for this indication, is a small molecule oral drug targeting inflammasome pathway activation that is central to the development and progression of pericarditis.
Toronto, Ontario – (April 16, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company“), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial (“MAVERIC”) evaluating Cardiol’s lead drug candidate CardiolRx™ for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRx™ on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval.
MAVERIC is currently being initiated at pre-eminent cardiovascular clinical research sites throughout the United States under an Investigational New Drug application authorized by the United States Food and Drug Administration (“US FDA”). The MAVERIC Program and Phase III leadership comprises an independent committee of international thought leaders in pericardial disease and clinical trial design: Allan Klein, MD, CM from Cleveland Clinic (MAVERIC Program Chair); Massimo Imazio, MD, FESC from University of Udine, Italy (MAVERIC Program Co-Chair); Paul Cremer, MD from Northwestern University (MAVERIC Trial Principal Investigator); Allen Luis, MBBS, PhD from Mayo Clinic Rochester (MAvERIC-Pilot Principal Investigator); Antonio Abbate, MD, PhD from University of Virginia; and, Stephen Nicholls, MBBS, PhD from Monash University, Melbourne, Australia.
“Recurrent pericarditis remains a challenging condition to manage and can significantly impact patients’ quality of life. There is a pressing need for new treatment options earlier in the care pathway, before resorting to second- and third-line therapies such as corticosteroids or IL-1 blockers,” commented Paul C. Cremer, MD, MAVERIC Trial Principal Investigator. “In collaboration with research centers across the United States, Canada, and Europe, we look forward to completing this important study of a new oral therapy with the potential to improve the treatment paradigm for this underserved patient population.”
“Initiation of the MAVERIC Phase III trial is an important milestone in our Company’s efforts to provide a more accessible, non-immunosuppressive therapeutic option for thousands of pericarditis patients. We congratulate Dr. Cremer and his colleagues at Northwestern for recruiting MAVERIC’s first patient and we are grateful for the interest shown by our collaborators from other leading pericardial disease centers who will be participating in the study,” said David Elsley, President and CEO of Cardiol Therapeutics. “Based on the strength and consistency of the data from our Phase II MAvERIC-Pilot study, we believe that CardiolRx™ can make a meaningful difference in the lives of pericarditis patients.”
MAVERIC is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial designed to enroll 110 patients with recurrent pericarditis at approximately 20 clinical sites across the United States, Canada, and Europe. Patients who have been treated with an interleukin-1 (“IL-1”) blocker for at least 12 months and are scheduled to have this treatment discontinued, will be randomly assigned to receive either CardiolRx™ or placebo following cessation of the IL-1 blocker. Discontinuation of IL-1 blocker therapy is associated with a high risk for recurrence and has been reported to occur within 12 weeks in up to 75% of patients. The primary clinical objective of the trial will be to assess the impact of CardiolRx™ versus placebo on freedom from a new episode of recurrent pericarditis at 24 weeks. Other clinical endpoints include time to a new episode of pericarditis recurrence, and changes in patient-reported pericarditis chest pain score and changes to the inflammatory marker C-reactive protein.
MAVERIC, formerly referred to as MAVERIC-2, follows positive results from Cardiol’s Phase II MAvERIC-Pilot study. Data from MAvERIC-Pilot were previously reported on November 18 at the American Heart Association Scientific Sessions 2024 and showed that patients experienced marked and rapid reductions in both pericarditis pain and inflammation that were maintained throughout the study. In addition, the results demonstrated a substantial reduction in pericarditis episodes per year. Treatment with CardiolRx™ was shown to be safe and well tolerated in a patient population who presented with a high degree of disease burden.
Mr. David Elsley is a business leader with a proven track record of developing, financing and managing all aspects of corporate development in biotechnology and high-growth organizations.
In 1990, Mr. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. Mr. Elsley assembled a team of management, directors and scientific advisors comprising industry professionals and thought leaders from North America and Europe.
Mr. Elsley managed and directed Vasogen’s growth from start-up to an organization employing over 250 people with operations and R&D programs in Canada, the United States and Europe. He established the research and development infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies from concept to completion of international multi-center pivotal phase III clinical trials involving 2,500 patients. Vasogen went public on the TSX and the Nasdaq, raising over $200 million to support corporate development and reached a market capitalization of over US$ 1 billion.
Mr. Elsley holds a Master of Business Administration from the Richard Ivey School of Business, University of Western Ontario.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND SEVEN HUNDRED TWENTY USD BY LFG EQUITIES CORP FOR A ONE DAY CRDL AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
BNC Accelerates Toward Global #1 BNB Treasury With $160M Purchase
CEA Industries and 10X Capital, with the support of YZi Labs, announce $500 Million Private Placement to Establish Largest Publicly-Listed $BNB Treasury Company in the World
Nano Labs Invests in BNB Strategic Reserve Company CEA INDUSTRIES INC. to Further Strengthen BNB Reserve Strategy
________________________
Hello Everyone,
We saw another high flyer with last Wednesday’s profile. It closed under $10 on the session and was red. Since then it has been nothing but green sky’s and it just hit 14.77. That is almost 50% in just 4 sessions after we told said it had all the trademarks of a potential bounce play.
There is a good chance that this one might have come across your screen already as a few weeks back this one made a massive splash when it was trading under VAPE, the former ticker that was just changed days ago.
Now it is trading under the ticker BNC.
Back on the 28th the company the company made a MASSIVE announcement about going in another direction and it ran up over $80 on all the hype and algorithms. It was a MASSIVE day for the company. It traded just under a Billion Dollars before closing just under $58 Just to give you an idea how massive this news was, you can see it closed the day before in the 8 dollar range.
It almost hit 83 which is 1000% over the previous close. It did close up 540% on the session.
We saw the usual profit taking after a monumental move like that.
BNC came right back and dropped some huge news basically stating that the plan they just laid out is well under way.
BNC Accelerates Toward Global #1 BNB Treasury With $160M Purchase
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — BNB Network Company, the treasury management business of CEA Industries Inc. (Nasdaq: BNC), today announced the purchase of 200,000 BNB tokens, furthering its momentum toward becoming the largest corporate holder of BNB globally. This acquisition follows a landmark $500 million private placement, led by 10X Capital in partnership with YZi Labs, to fund a treasury strategy centered exclusively on BNB—now the company’s primary reserve asset.
A Strategic Pivot to BNB
Under its new Nasdaq ticker, BNC (formerly VAPE) is steering its treasury management to focus solely on building significant exposure to BNB.
Leadership has been restructured to support this crypto-first strategy: David Namdar, co-founder of Galaxy Digital, steps in as CEO, joined by Russell Read, former CIO at CalPERS, and former Kraken director Saad Naja.
10X Capital Founding Partner Hans Thomas and Partner Alexander Monje have also joined the company’s Board of Directors.
Why BNB
BNB, the native token of BNB Chain—Now the #1 on-chain trading infrastructure—is currently the fourth-largest cryptocurrency by market capitalization. With $12.3 billion in total value locked (TVL), it ranks as the third-largest chain (by TVL) and shows strong potential for further growth.
Deflationary token supply, fast growing on-chain activity, attractive DeFi yields, and potential catalysts such as a BNB spot ETF make the asset a compelling long-term play. For BNC, BNB is not just a strategic reserve, it’s a growth opportunity aligned with one of the strongest DeFi ecosystems in the industry.
Why This Matters
The $160 million purchase confirms BNC’s role as the leading institutional BNB treasury globally.
BNB boasts 250 million users and an average daily trading volume of $9.3 billion as of July 2025. Yet, it remains under-represented in the U.S.
BNC aims to bridge that gap, bringing greater institutional presence to the BNB ecosystem.
What’s Next
BNC plans to continue purchasing BNB until the initial treasury capital is fully deployed and may tap up to $750 million more via its warrant structure. If fully exercised, total proceeds could approach $1.25 billion for additional BNB acquisitions.
This positions BNC to capture a unique market opportunity—offering U.S. and global investors exposure to BNB without requiring them to hold the token directly.
By securing $160 million in BNB and leveraging a robust $500 million private raise, BNC has established itself as the world’s leading corporate BNB treasury, signaling both confidence in BNB Chain’s long-term trajectory and a commitment to bringing BNB into the spotlight for U.S. institutional investors.
About YZi Labs
YZi Labs manages over $10 billion in assets worldwide with an “impact first” approach—believing strong returns follow meaningful change. The firm invests across all stages, with a focus on Web3, AI, and biotech. Its portfolio spans 300+ projects in 25+ countries across six continents, with over 65 companies emerging from its incubation programs. Follow YZi Labs on X for more.
About 10X Capital
10X Capital is a next-generation investment firm driving digital transformation in assets and infrastructure. It connects institutional capital with exceptional opportunities worldwide through public and private markets, portfolio companies, treasury operations, and an affiliated investment bank. With expertise in corporate development, asset and treasury management, and capital markets, 10X Capital builds Digital Asset Treasury companies that create disruptive strategies with global impact. Follow 10X Capital on X for more.
CEA Industries and 10X Capital, with the support of YZi Labs, announce $500 Million Private Placement to Establish Largest Publicly-Listed $BNB Treasury Company in the World
Upsized PIPE offering with potential to deliver up to $1.25 billion of gross proceeds
Offering consists of a common equity PIPE delivering $500M in gross proceeds ($400M in cash and $100M in Crypto), plus up to $750M in cash which may be received from exercised warrants to be issued in the private placement (assuming 100% of warrants are exercised).
The proceeds of the offering by CEA Industries Inc. (Nasdaq:VAPE-NOW BNC) will be used to establish the largest publicly listed BNB Chain digital asset treasury strategy in the world.
$BNB is the fourth largest cryptocurrency in the world, with $100B+ market cap, and provides the treasury with opportunities to generate income and rewards on the BNB Chain and Binance ecosystem, the world’s #1 digital assets infrastructure by volume, with over 280 million users in over 180 countries.
The BNB treasury strategy will be led by incoming CEO David Namdar (Co-founder of Galaxy Digital and Senior Partner at 10X Capital), incoming CIO Russell Read (former CIO of CalPERS and CIO of 10X Capital) and Saad Naja (former director at Kraken and one of the executive board of directors of global retail brokerage firm Exinity).
10X Capital, who also served as financial advisor to Nakamoto, will serve as the asset manager of the BNB treasury strategy, with the support of YZiLabs.
The transaction is expected to close on or around July 31, 2025.
Louisville, CO, July 28, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq:VAPE) (the “Company”) and 10X Capital, with support from YZi Labs, today announced the pricing of an oversubscribed and upsized above-the-market PIPE financing, positioning the Company to become the largest publicly traded BNB Treasury Company in the United States.
This milestone marks a significant evolution from 10X Capital & YZi Labs’ initial announcement in early July, officially bringing $BNB—a top-four digital asset token with over $100 Billion in market capitalization—into U.S. public markets at institutional scale through a dedicated treasury vehicle.
Following the closing, the Company intends to begin deploying funds to acquire BNB, creating a gateway for institutional and retail investors to participate in the BNB Chain ecosystem, which powers millions of users and decentralized applications worldwide.
Following closing, the Company’s management team is expected to include significant institutional expertise, including from incoming CEO David Namdar (Co-Founder, Galaxy Digital and Senior Partner, 10X Capital), incoming CIO Russell Read (CIO, 10X Capital and former CIO of CalPERS, Deputy CIO of Deutsche Bank Asset Management) and Saad Naja (former director at Kraken and one of the executive board of directors of global retail brokerage firm Exinity).
The Company expects to be positioned among the largest publicly traded vehicles offering exposure to a single Layer-1 blockchain following closing of the PIPE.
“BNB Chain is one of the most widely used blockchain ecosystems globally, yet institutional access has been limited until now. By creating a U.S.-listed treasury vehicle, we are opening the door for traditional investors to participate in a transparent way. This is a significant step in bridging digital assets and mainstream capital markets,” said incoming CEO David Namdar.
“Institutional-grade exposure to BNB is attractive because it is driven by fundamentals rather than speculation. BNB powers one of the largest ecosystems in blockchain — with real network utility across DeFi, payments and enterprise applications. By creating a treasury vehicle, we’re allowing institutions to participate in that growth story in a way that aligns with their need for transparency and long-term value, rather than short-term trading opportunities,” said incoming CIO Russell Read.
BNB Treasury Strategy & Institutional Roadmap
Following closing, the Company expects to:
Build an initial BNB position with plans to significantly scale holdings over the next 12–24 months via a best-in-class capital markets program incorporating ATM sales and other proven strategies.
Evaluate staking, lending and other opportunities throughout the Binance ecosystem to generate revenue from the BNB Treasury, while maintaining a conservative risk profile.
“When YZi Labs first announced our support earlier this month, it was because we recognized the institutional potential of a publicly listed BNB treasury vehicle.” said Ella Zhang, Head of YZi Labs. “With the successful announcement of this PIPE, that conviction is now validated. We’re proud to see this vision come to life — expanding BNB’s utility and institutional access in a meaningful and sustainable way.”
“Treasury companies have proven to be the cleanest, most transparent gateway for institutions to access digital assets. With BNB powering hundreds of millions of users globally, this marks the right time for a well-capitalized BNB treasury company to enter the U.S. market,” said Hans Thomas, Founder and CEO of 10X Capital.
Market Context: A New Asset Class for Wall Street
The PIPE highlights a growing trend where publicly traded treasury companies are emerging as a new asset class for U.S. investors, building on the success of Bitcoin-focused vehicles such as MicroStrategy and recent treasury players such as Sharplink Gaming, Bitmine Immersion, and DeFi Development Corp. Importantly, ongoing crypto regulatory bills and signals from U.S. lawmakers are injecting confidence and laying the groundwork for greater market participation, providing institutional investors with increased regulatory certainty. Unlike those Bitcoin-focused and other treasury plays, this treasury vehicle is exclusively dedicated to the BNB Chain, offering exposure to a fast-growing Layer-1 network with strong DeFi, NFT and Web3 adoption.
Trading & Next Steps
The Company’s common stock will continue to trade on the Nasdaq Capital Market under the ticker “VAPE”, with the updated treasury strategy effective immediately following the closing, which is expected to take place on or about July 31, 2025. The Company will emphasize transparency and verification of holdings, strong engagement with the BNB ecosystem and community. Additional updates on BNB acquisitions, treasury growth and governance measures are expected in the coming weeks.
Nano Labs Invests in BNB Strategic Reserve Company CEA INDUSTRIES INC. to Further Strengthen BNB Reserve Strategy
HONG KONG, July 30, 2025 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider in China, today announced that it has entered into a strategic equity investment agreement with CEA INDUSTRIES INC. (Nasdaq: VAPE), a company focused on building BNB reserves.
Under the terms of the agreement, Nano Labs subscribed for 495,050 shares of Class A common stock of CEA INDUSTRIES INC. at a price of US$10.10 per share. The investment also includes 495,050 warrants with an exercise price of US$15.15 per share. If fully exercised, Nano Labs could hold up to 990,100 shares of the company.
This investment constitutes part of CEA INDUSTRIES INC.’s ongoing US$500 million Private Investment in Public Equity (PIPE) financing plan. Proceeds from this tranche are primarily designated for the acquisition of BNB, with the remainder allocated toward working capital, transaction fees, and general corporate purposes.
This strategic transactional move represents another key milestone in Nano Labs’ ongoing strategic initiative to build cryptocurrency reserves. The Company is committed to enhancing its reserve position across major public chain ecosystems through strategic partnerships and further optimizing its crypto asset allocation structure.
As of the date of this announcement, Nano Labs holds approximately 128,000 BNB in total.
The closing under the agreement is subject to customary closing conditions. There is no guarantee that closing will happen in full or at all. Investors should not place on due reliance on this press release.
About CEA Industries Inc. CEA Industries Inc. (Nasdaq: VAPE) is a growth-oriented company that has focused on building category-leading businesses in regulated consumer markets, including the high-growth, Canadian nicotine vape industry. CEA Industries targets scalable operators with strong regulatory alignment, defensible market share, and high-margin business models. Following the closing of the PIPE, CEA intends to adopt a BNB Treasury strategy, offering a gateway for institutional and retail investors to participate in the BNB Chain ecosystem, Binance Layer-1 blockchain ecosystem coin.
About Nano Labs Ltd. Nano Labs Ltd is a leading Web 3.0 infrastructure and product solution provider in China. Nano Labs is committed to the development of high throughput computing (“HTC”) chips and high performance computing (“HPC”) chips. Nano Labs has built a comprehensive flow processing unit (“FPU”) architecture which offers solution that integrates the features of both HTC and HPC. In addition, Nano Labs has actively positioned itself in the digital assets space, adopting BNB as its primary reserve asset. It has reserved in mainstream digital currencies including BNB and BTC, and established an integrated platform covering multiple business verticals, including HTC solutions and HPC solutions*. For more information, please visit the Company’s website at: ir.nano.cn.* According to an industry report prepared by Frost & Sullivan.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY BNC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Clients and Partners Include: US Dept. of Defense, Defense Intelligence Agency, Homeland Security, US Navy and Many Other Major Private Sector Companies
2024 Total Revenue of 17.8 Million with Adjusted EBITDA of $2.3 Million, +58.9% y/y with Expanded Margin of 12.9% vs $1.4 Million in FY2023 & Net Income of $1.2 Million Marking First Full Year of Net Profitability
$89 Million In Total Contracts With New Deals Happening, A New BTC And ETH Treasury Unit
IQST – IQSTEL and Cycurion (CYCU) Sign MOU for Equity Exchange and Alliance to Build a Next-Gen AI-Driven Powerhouse with Half of the Stock to be Distributed as a Dividend to Shareholders
________________________
Hello Everyone,
We are coming right back to with another company to look at for Friday’s session. IQST closed up about 6% after coming out with explosive news. For Friday’s session we want to focus on the other company featured in that press release, which we will revisit in a second.
This one saw a similar 6% increase coupled with a big spike in interest.
CYCU is a lot cheaper than IQST at just .36, so if 8 bucks is a little too pricey and isn’t in your roundhouse then CYCU is something that should be on your radar heading into the weekend.
Cycurion, Inc. (Nasdaq: CYCU) is a tech-enabled cybersecurity firm that serves some of the most complex government agencies and corporations in the world including Fortune 100 and 500 Companies. Founded by internet pioneer Emmit McHenry — who directly oversaw the first internet protocols and the creation of .com domains — CYCU brings an unparalleled blend of vision, technology, and experience to every project. More than just an MSSP or strategic advisor, CYCU is a full-service security partner capable of guiding any organization through the modern cyber threat lancscape. Cybersecurity has become an increasingly critical issue as illustrated by many top level media sources devoting high profile features on the subject.
CYCU is committed to surpassing expectations and delivering incomparable value to its clients and partners. CYCU achieves this goal by providing Network Communications and Information Technology Security services and solutions that are custom-tailored to the client’s environment, as well as level of need. CYCU is built on a foundation of experts in Network Communications and Information Technology who possess unrivaled security expertise and experience.
The flagship Cycurion ARx platform is a unified cybersecurity solution for protecting critical digital assets. Multi-layer protection is focused on inspecting requests to and responses from a digital asset. This non-invasive approach wraps around a digital asset — without hardware requirements or cloud installations — while keeping the client’s IP completely private. With every request inspected, malicious threats are logged and blocked in real-time before reaching the asset. This CYCU multi-layer model of cybersecurity is intended to thwart potential attackers via an expanding set of protective layers.
For more than a decade, Cycurion has provided expansive, capable and adaptive IT solutions to major government agencies, including the U.S. Department of Defense, the Department of Homeland Security, the U.S. Navy and the Defense Intelligence Agency, among others. In the private sector, it protects the IT infrastructures, digital assets and networks of a slew of Fortune 100 and 500 companies. In the healthcare space, it recently inked a deal with the National Association of County and City Health Officials (NACCHO), the voice of the over 3,300 local health departments across the country.
Through its partnership with NACCHO, Cycurion will make available its Managed Security Services Platform (MSSP), Cyber Shield, to NACCHO members. This collaboration addresses key challenges in the healthcare industry and could be the framework for future partnerships in a market that is forecast to reach more than $878 billion by 2034.
According to Cycurion, there is a severe shortage of trained cybersecurity professionals in the healthcare industry at a time when there are rapidly evolving security compliance requirements. What’s more, many healthcare facilities fall short when it comes to comprehensive cybersecurity programs, policies and procedures, making them vulnerable to data breaches and cyber attacks. Add the fact that there is low cybersecurity awareness among employees, limited visibility into emerging threats and inadequate IT infrastructures, and it is no wonder there has been an explosion of data breaches and financial losses in the healthcare sector, reports Cycurion.
Cycurion’s Cyber Shield suite of tools addresses all those problems, equipping NACCHO members with enterprise-grade security solutions, expert guidance and cost-effective cybersecurity services tailored to the unique demands of local public health agencies, reports the company. The deal with NACCHO is expected to bring in $20 million in revenue for Cycurion.
The company has already secured $89 million in contracts, $69 million recently, including a $33 million contract renewal to enhance cybersecurity for state-level public higher education institutions over the next five years, a $22 million multi-year contract with a state police agency to upgrade and secure their communications infrastructure, a $6 million contract with a major municipal transportation agency for improved cybersecurity measures and $8 million in new contracts announced in June, further underscoring Cycurion’s position in the market.
The company’s growth is reflected in its financials – for the first quarter, Cycurion reported revenue of $3.9 million, gross profits that were up 95.4% year-over-year and gross margins 17.4% higher than last year’s first quarter, which the company credited to its focus on capturing and retaining more profitable business.
IQST – IQSTEL and Cycurion (CYCU) Sign MOU for Equity Exchange and Alliance to Build a Next-Gen AI-Driven Powerhouse with Half of the Stock to be Distributed as a Dividend to Shareholders
Both Companies combined have Invested Millions of Dollars over the last 5 years into Proprietary AI assets and technologies.
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — IQSTEL Inc. (NASDAQ: IQST) (“IQSTEL”) and Cycurion Inc. (NASDAQ: CYCU) (“Cycurion”) today announced the signing of a Memorandum of Understanding (MOU) to become mutual equity partners following a planned $1 million stock exchange, with half of each company’s exchanged shares to be distributed as a dividend to enhance shareholder value. This milestone marks a significant step in the two companies’ collaboration and sets the stage for creating a powerhouse in AI-driven cybersecurity for the global telecommunications industry.
This transaction is designed to unlock shareholder value, while being strategically timed for both companies as the products and services of IQSTEL and Cycurion are largely insulated from potential disruptions caused by changes in U.S. tariffs and their economic consequences.
The agreement also strengthens the companies’ alliance by integrating complementary market strengths and uniting both organizations’ AI-focused Research and Development departments with a shared mission: to deliver next-generation cybersecurity solutions tailored for telecom industry, government institutions, and enterprise clients worldwide.
The Stock Exchange – Foundation for a Mutual Equity Partnership
Under the MOU, each company will issue $1 million worth of its common stock to the other.
The number of shares will be based on the lower of:
1. The Nasdaq Official Closing Price on the trading day immediately preceding the signing of the binding agreement; and
2. The average Nasdaq Official Closing Price over the five (5) trading days immediately preceding the signing of the binding agreement.
Subject to board and regulatory approvals, each company intends to distribute up to 50% of the shares it receives to its existing shareholders as a stock dividend —transforming IQSTEL shareholders into Cycurion shareholders, and vice versa.
This transaction is designed to unlock shareholder value by creating a mutual equity structure that both companies view as a “sibling company” relationship, ensuring each directly benefits from the other’s success. Importantly, both IQST and CYCU are actively traded stocks with weekly liquidity in the millions of U.S. dollars, which is believed to be highly advantageous for the combined ~30,000 shareholders across both companies.
In addition, the stock swap opens the door for powerful cross-selling opportunities: IQSTEL will be able to introduce its Telecom, Fintech, and AI-driven services to Cycurion’s established customer base, while Cycurion will gain access to offer its advanced cybersecurity solutions to some of the largest telecom operators in the world through IQSTEL’s extensive global network.
One Unified AI R&D Mission
Both IQSTEL and Cycurion operate advanced AI research and development teams, each with complementary expertise that makes this collaboration particularly powerful.
IQSTEL has been developing proprietary AI services through its in-house IQSTEL Intelligence division (www.realityborder.com), launching two proprietary products: www.Airweb.ai — a multilingual AI web/phone/messaging agent — and www.IQ2Call.ai — an AI-powered call center agent. Most recently, IQSTEL Intelligence was engaged by ONAR to develop a full suite of AI-driven sales support tools designed to streamline and enhance ONAR’s daily sales operations.
Meanwhile, Cycurion has been working to deliver the next generation of AI-based cybersecurity services, aimed at protecting telecom networks, government infrastructure, and enterprise systems.
Following the stock exchange, the companies except to join forces, pool resources, and align strategic focus to:
deliver a proprietary, joint AI-driven cybersecurity solution, integrating IQSTEL’s AI innovations with Cycurion’s cybersecurity expertise.
enhance Cycurion’s internal processes and customer support responsiveness using IQSTEL’s advanced AI virtual agents.
accelerate innovation cycles and bring cutting-edge, next-generation cybersecurity products to market faster.
With this mutual equity transaction, IQSTEL and Cycurion are set to potentially become a true AI powerhouse — combining complementary strengths in AI innovation and cybersecurity. The market has yet to fully realize the potential value of this collaboration, which positions both companies to capture significant new opportunities in the rapidly evolving AI-driven cybersecurity landscape.
Complementary Market Strengths
The alliance is reinforced by the complementary reach of both companies:
Cycurion has a strong presence in the U.S. market and deep relationships within government and institutional sectors.
IQSTEL has a global footprint in telecommunications, with established commercial relationships spanning more than 600 telecom operators worldwide.
Together, the companies expect to cross-sell solutions, penetrate new markets, and open revenue streams that neither could fully capture alone.
There is more to come in their Mutual Equity Partnership.
While this stock exchange is a transformative milestone, both companies emphasize that this is just the beginning of their mutual equity partnership. This transaction opens the door to a more intensive relationship in the future. The MOU outlines an initial 60-day exploratory period; however, the companies plan to execute the definitive agreement within the next 30 days — completing due diligence, securing internal approvals, and advancing toward implementation.
In parallel, both parties will work to identify further opportunities for collaboration, potentially including joint ventures, expanded R&D initiatives, and integrated go-to-market strategies designed to accelerate growth and maximize value for their combined shareholder base.
The companies will announce the registration date for the planned dividend in a separate joint communication once the definitive agreement is executed.
Leandro Iglesias, CEO of IQSTEL, stated:
“This mutual equity partnership marks the creation of a powerhouse in AI-driven cybersecurity. By combining our resources, complementary customer bases, and innovation teams, we are setting a new standard for what’s possible. The benefits to our combined 30,000 shareholders are immediate — they will now own part of both companies, and our shared market liquidity makes that ownership all the more valuable.”
L. Kevin Kelly, CEO of Cycurion, commented:
“This is more than a stock swap. It’s the start of a long-term equity partnership that we expect will accelerate innovation and growth for both companies. We are confident that our U.S. and government market strength when combined with IQSTEL’s global telecom presence is a powerful combination that positions us for significant impact.”
About IQSTEL Inc.
IQSTEL Inc. (NASDAQ: IQST) is a U.S.-based, publicly traded company specializing in high-growth technology areas, including telecommunications, fintech, AI, and cybersecurity. With a presence in over 21 countries and commercial relationships with more than 600 telecom operators, IQSTEL is on a mission to reach $1 billion in annual revenue by 2027 through strategic acquisitions, organic growth, and high-margin tech solutions.
Cycurion (NASDAQ: CYCU) Launches “Cycurion Crypto” Subsidiary with $10 Million Treasury Allocation to Acquire Ethereum and Bitcoin
MCLEAN, Va., July 15, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion”), a leading cybersecurity and digital infrastructure company, today announced the formation of a wholly owned subsidiary, Cycurion Crypto, as part of its strategic initiative to position the Cycurion within the expanding digital asset ecosystem while strengthening its balance sheet and accelerating its growth strategy.
Cycurion will allocate $10 million pending board approval from the proceeds from future sales under its existing $60 million equity line of credit (ELOC) to establish a crypto treasury, focused on acquiring Ethereum (ETH) and Bitcoin (BTC) as long-term holdings. This move enables Cycurion to diversify its cash reserves and capture potential upside in the blockchain economy while maintaining its disciplined capital allocation approach.
“The launch of Cycurion Crypto aligns directly with our mission to build secure digital infrastructure while actively participating in the evolving blockchain landscape,” said Kevin Kelly, CEO of Cycurion. “We see Bitcoin and Ethereum as foundational elements of the digital economy, and our strategic allocation enables Cycurion to enhance shareholder value while positioning ourselves for opportunities in blockchain-based cybersecurity.”
Supporting Growth and Capital Strategy
Cycurion Crypto will:
enhance Cycurion’s investor appeal by diversifying reserves and aligning with tech-forward capital markets, creating an additional narrative to support future capital raises while maintaining a strong liquidity position.
position Cycurion within blockchain security, an emerging intersection with the Company’s core zero-trust and cybersecurity offerings, enabling future revenue opportunities from crypto-native clients and infrastructure projects.
strengthen Cycurion’s market positioning by appealing to institutional and retail investors seeking exposure to blockchain innovation through a disciplined, regulated public company structure.
create optionality for future spinouts, partnerships, or blockchain-focused grant funding to accelerate growth while limiting dilution.
The crypto treasury will be managed under Cycurion Crypto with a focus on long-term holding, operational transparency, and regulatory compliance, ensuring alignment with Cycurion’s standards of security, risk management, and fiduciary responsibility. All crypto purchases will be made in sole discretion of management at then prevailing prices. Ethereum (ETH) and Bitcoin (BTC) are highly volatile assets and we can provide no assurances that our investments will be profitable.
Cycurion, Inc. Secures Over $8 Million in New Contracts, Strengthening Cybersecurity Leadership
Contract awards build upon Cycurion’s other recent sales wins that have led to record backlog and positioned the company for a strong second half to 2025
MCLEAN, Va., June 25, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces the award of several new contracts totaling over $8 million. These agreements, secured with government and commercial clients, reinforce Cycurion’s position as a trusted partner in protecting critical digital infrastructure.
The contracts, spanning program management, cybersecurity, and disaster recovery services, include a significant $6 million agreement with a major municipal transportation agency to deliver comprehensive IT and cybersecurity solutions. Over $1 million of the total contract value will begin billing in June 2025, with the remainder commencing in the third quarter of 2025. These engagements are set to run for the next 12 to 18 months, leveraging Cycurion’s proprietary ARx platform for real-time threat detection and multi-layered protection.
“Securing over $8 million in new contracts reflects our dedication to delivering innovative, AI-enhanced cybersecurity solutions,” said L. Kevin Kelly, Cycurion Chairman and CEO. “These awards, combined with our strategic focus on high-margin clients, position us for robust growth as we safeguard organizations across diverse sectors.”
Cycurion’s ARx platform, a turnkey web application protection and managed security solution, continues to drive its competitive edge by offering scalable security without hardware or cloud dependencies. With a record backlog and strategic partnerships, Cycurion is poised for sustained success in 2025.
Cycurion Announces a Strategic Partnership with AgileBlue to Deliver Advanced AI-Powered Cybersecurity Operations Across North America
MCLEAN, Va., July 02, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a leading provider of cybersecurity services to public and private sectors, today announced a strategic partnership with AgileBlue, an AI-powered Security Operations (“SecOps”) platform provider. Under the terms of the agreement, Cycurion will serve as an authorized reseller of AgileBlue’s full suite of cybersecurity solutions, including its next-generation Managed SecOps-as-a-Service, Security Information and Event Management (SIEM), Security Orchestration, Automation and Response (SOAR), and Extended Detection and Response (XDR) platforms.
This partnership strengthens Cycurion’s capabilities to deliver continuous threat-monitoring, autonomous response, and machine-driven risk analysis via AgileBlue’s AI-powered SecOps platform. It will also enable both companies to bring enhanced threat detection, compliance, and incident response to mid-market and enterprise clients across North America.
“Today’s announcement reflects our shared commitment to staying ahead of an increasingly complex threat landscape,” said Kevin Kelly, CEO of Cycurion. “By integrating AgileBlue’s autonomous, AI-driven security capabilities into our managed service portfolio, we are accelerating our mission to provide measurable cyber resilience for our clients across government and commercial sectors.”
The agreement allows Cycurion to offer AgileBlue’s AI-powered SecOps platform under its own brand, Cyber Shield, complete with a customized portal and 24/7 SecOps services backed by AgileBlue’s U.S.-based cyber analysts. Clients will benefit from real-time, threat-hunting, guided alerts, and automated triage powered by Sapphire AI, which delivers analyst-level insights and autonomous response actions, dramatically reducing false positives and enabling faster decision-making.
“Cycurion brings expertise and trusted customer relationships to this collaboration,” said Tony Pietrocola, Co-Founder & President of AgileBlue. “Cycurion’s leadership in compliance-driven environments and its commitment to innovation make it an ideal partner to expand our footprint in regulated and high-risk sectors.”
AgileBlue’s second quarter of 2025 platform release includes enhancements, including bi-directional ConnectWise integration for MSPs, improved artifact navigation for faster forensic analysis, and new AI-driven case summarization tools. Together with Cycurion’s services, these features will be deployed to help organizations proactively identify, assess, and neutralize cyber threats before they escalate.
The partnership underscores both companies’ strategic focuses on empowering cybersecurity teams with automation, advanced analytics, and proactive protection capabilities which are essential components in today’s evolving digital risk ecosystem.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWO THOUSAND TWO HUNDRED SEVEN AND FIFTY CENTS USD BY CORPORATE ADS LLC FOR A ONE DAY CYCU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
IQST Runs a Diversified Business with Divisions Focused on Telecommunications, Fintech, Electric Vehicles, Artificial Intelligence with 9 acquisitions since inception
They just reported $128.8 million in preliminary unaudited revenue for the first half of 2025, with June alone contributing $27.3 million
IQST Announces $2 Debt Reduction Per Share, $400 Million Run Rate in Q3 (Ahead of Schedule), and Analyst Coverage Targeting $18-$22 Price Range
In 2024, IQSTEL reported $283 million in revenue while their market cap remained at only about 10% of that figure — They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST
Hello Everyone,
We have something familiar back on our radar ahead of Thursday’s open.
The first time we looked at It, we saw an opening on that session of 8.92. Then the next session it hit 14.70 on record interest. It was a huge 65% overnight winner.
If you haven’t researched IQST in the past, we are urging you to take a look at it right now here at these levels.
This one has sat in a tight range all of July and it is sitting right now at a place where it definitely has room to run. The ceiling on this company is HIGH with their massive revenues and big relationships already in place.
The growth alone is jaw dropping as the company claims to be on track to 1 Billion in Revenues by 2027. It just up-listed to the Nasdaq back in May.The CEO says the company came to the Nasdaq with 20,000 shareholders.
IQST is a multinational technology company offering cutting-edge solutions in Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Telecom, High-Tech Telecom Services (eSIM, roaming, cloud), with over 600 global business relationships.They deliver high-value, high-margin services to its extensive global customer base.r
In 2024, IQSTEL reported $283 million in revenue, yet their market cap remained at only about 10% of that figure. They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST.
• Robust Telecom Operations – iQSTEL provides international wholesale voice and SMS transport for more than 35 leading telecom operators—including Verizon, Vodafone, and China Mobile— and hundreds of Tier 2 carriers via interconnects with over 600 carriers across 20+ countries. In the past year, voice traffic volume increased 24% and SMS traffic rose 23%, underscoring growing demand and customer satisfaction.
• Relationship-Driven Industry, Relationship-Driven Company – Success in international telecom hinges on experience, trust, and network reach. iQSTEL’s core competitive edge lies in management’s extensive global relationships. CEO Leandro Iglesias and his executive team bring decades of deep industry expertise, which they’ve used to convert personal contacts into longstanding commercial relationships and favorable interconnection agreements.
• Asset-Light Model = High Returns – Rather than investing in capital-intensive infrastructure, iQSTEL leases capacity in an oversupplied global telecom market. This asset-light approach significantly enhances return on investment and operational flexibility, enabling the company to scale rapidly and pivot as market opportunities arise.
• Disciplined, Strategic M&A Platform – iQSTEL has completed nine acquisitions since going public in 2018. These deals have been carefully sourced through existing industry relationships—every acquired CEO was personally known to Mr. Iglesias. Post-acquisition, these founders remain in place under earn- out agreements, preserving operational continuity and customer relationships. The company’s strategy of acquiring an initial 51% stake enables efficient capital allocation while maintaining majority control.
• Accelerating Revenue, Near-Term Profitability – Revenue grew 96% last year to $283 million, and we estimate that it is on the cusp of generating positive EBITDA. Management guides to a $400 million annualized revenue run rate by year-end, including a recent acquisition expected to contribute approximately $85 million in additional annual revenue. The longer-term goal is $1 billion in revenue, positioning iQSTEL alongside peer leaders such as IDT (NYSE-IDT) and Cogent (NASDAQ-CCOI).
• Attractive Valuation with Significant Upside – Telecom comparables trade at an average EV/EBITDA multiple of 9.2x 2026E, with iQSTEL’s closest comps (IDT and Cogent) trading at a 15% premium.
iQSTEL is a Miami-based telecom services company providing international services under a unique asset-light model. The business was founded by the former head of CANTV’s international business in 2008 as Etelix and then merged with a public shell company to go public in 2018. Since then, the company has completed nine acquisitions, with revenue growing rapidly, and more growth is expected. This year, it is consolidating acquisitions, moving both voice and SMS traffic to its operating subsidiaries with the lowest cost routing via international agreements. It is also working with its vendor to consolidate its operations onto a single platform.
The company has four key competitive advantages:
• Exceptional Industry Relationships – CEO Leandro Iglesias brings 27 years of telecom experience, including leadership at CANTV—formerly Venezuela’s top-tier national carrier and once partly owned by Verizon and Telefónica. His personal network spans the globe and includes current executives at many of the world’s largest carriers.
• Strategic Customer Acquisition – Management has leveraged its relationships to secure over 35 major international telecom customers and hundreds of tier 2 customers. These are high-volume, recurring relationships that drive consistent growth and reduce churn risk.
• Buyer Advantage in Oversupplied Market – Management also utilizes the same connections to secure the lowest-cost routing and termination agreements with global telecom carriers. Telecom is an opaque industry, and personal connections are important in negotiating favorable terms. The company benefits because the telecom industry has overbuilt, deploying too many network assets, so negotiations favor buyers like iQSTEL.
• Proven Acquisition Strategy – Every acquisition the company has completed has been of a company founded and run by an entrepreneur that Mr. Iglesias has known personally for many years. His modus operandi is to acquire an initial 51% stake, keep management on board, and give them earn-outs for continuing to perform after the acquisition.
iQSTEL is the Combination of Nine Acquisitions
Acquisitions are a key to the company’s growth strategy. To date, it has completed nine acquisitions to get the company to its present state of five operating voice telecom subsidiaries, two operating SMS subsidiaries, two fintech subsidiaries, and one metaverse joint venture.
Consideration paid for the eleven acquisitions has totaled $17.57 million, including the reverse merger of the CEO’s original business into a shell company. By comparison, the company has a roughly $30 million market cap, only owns 51% stakes in six business units and a 75% stake in one, with 100% stakes in only the original Etelix and QGlobal SMS acquired in 2020. To bring its stake up to 100% in each of its business units would require an estimated $11.3 million at the original purchase prices; however, much of this is expected to be paid in shares.
The founders have been known professionally to the CEO for several years and are willing to stay on and run the business with earnouts for performance. Keeping the founders in place is important because they have personal relationships with the customers.
Since Inception, iQSTEL Has Completed Nine Acquisitions
MAIN CUSTOMERS
IQST – IQSTEL and ONAR – ONAR Join Forces to Disrupt Traditional Marketing with AI Agents
Latest Deployment of AIRWEB Underscores IQSTEL’s Expansion into High-Tech, High-Margin Verticals — Driving Forward Its $1 Billion Revenue Strategy
NEW YORK, July 29, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a multinational telecommunications and technology company, is pleased to announce a new commercial agreement with ONAR (OTCQB: ONAR) for the deployment of AIRWEB AI agents, marking a strategic advancement in IQSTEL’s rollout of high-tech, high-margin services aligned with its path to $1 billion in revenue.
As part of this collaboration, IQSTEL will provide dedicated and secure AI agents for every ONAR account manager. These text-based assistants are integrated directly into the AIRWEB platform, empowering ONAR’s commercial team with real-time insights, campaign intelligence, and operational efficiency — without the need for additional infrastructure.
“This is much more than a software deployment — it’s a strategic partnership,” said Leandro Iglesias, President and CEO of IQSTEL. “ONAR knows our capabilities well, having worked closely with us as a marketing partner. After witnessing the power of IQSTEL Intelligence — through AIRWEB.ai, IQ2Call.ai, and RealityBorder.com — they’ve chosen to deploy our AI technology to lead in the marketing arena. This validates our vision and shows how we are transforming industries with AI.”
Key Benefits of the AIRWEB AI Agent Deployment:
Dedicated AI agents for each team member: Individual logins and secure access, tailored for every account manager.
Real-time commercial intelligence: Ask any client or campaign question and receive ready-to-use answers based only on relevant, verified data.
Always current: Daily ingestion keeps knowledge fresh without manual updates.
Enterprise-ready: Delivered on AIRWEB’s production AI stack, including secure pipelines on AWS and GCP.
Privacy by design: End-to-end encryption, regional data residency (EU in Spain; global in Virginia), and stateless compute.
Fast deployment: Full rollout within ~4 weeks.
Omnichannel marketing insights: Instantly view campaign KPIs (spend, impressions, clicks, sessions, conversions, revenue, geo breakdowns) from within any conversation.
Multi-language support: Global-ready with native capability in 57 languages.
This collaboration reflects IQSTEL’s strategy of delivering innovative, scalable solutions that generate attractive margins. AIRWEB joins IQ2Call and other cutting-edge products in IQSTEL’s AI suite — all of which leverage the company’s robust commercial platform, already trusted by over 600 telecom operators across more than 21 countries.
This is just the beginning of a new era where IQSTEL empowers enterprises to lead through AI.
About ONAR
ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network powering unparalleled marketing services that drive revenue growth through an integrated, AI-driven approach. Additionally, the Company’s technology incubator, ONAR Labs, is focused on identifying, developing, and commercializing innovative marketing technology solutions. For more information, visit www.onar.com.
IQST – IQSTEL Issues Recap Shareholder Letter Highlighting $2 Debt Reduction Per Share, $400 Million Run Rate in Q3 (Ahead of Schedule), and Analyst Coverage Targeting $18-$22 Price Range
Company Recaps Milestones After Two Months on NASDAQ: Accelerated Growth, Strengthened Balance Sheet, Launch of High-Margin Tech Products, and Strategic Acquisition of Globetopper
NEW YORK, July 21, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST) has released a shareholder letter reflecting on its strategic and financial achievements during its first two months trading on the NASDAQ. The letter outlines the company’s accelerating growth trajectory, successful execution of its high-margin technology strategy, strengthened capital structure, and enhanced institutional visibility.
In this letter, IQSTEL’s CEO shares key business highlights, including surpassing a $400 million revenue run rate earlier than projected, the launch of AI-powered platforms like IQ2Call.ai, and the addition of $60–70 million in revenue through the Globetopper acquisition. The company also emphasizes its $2-per-share debt reduction, improving shareholder value and positioning IQSTEL to achieve its long-term $1 billion revenue goal by 2027.
Dear Shareholders,
As we mark our second month trading on the NASDAQ, I want to take this opportunity to reflect on the tremendous progress we’ve made and share with you why we believe the road ahead for IQSTEL is not just promising — it’s transformative. The Board of Directors and officers of the company are both excited and honored to have hit these major milestones. We remain fully committed to creating long-term shareholder value and driving the continued growth of the company.
A Strong Start to 2025 – Accelerating Toward a New Era
We’ve reported $128.8 million in preliminary unaudited revenue for the first half of 2025, with June alone contributing $27.3 million — a clear sign that our commercial momentum is not just holding strong, but accelerating.
Starting July 1st, we began consolidating revenues from our newly acquired subsidiary, Globetopper, which is expected to add an additional $5 to $6 million per month. With this acceleration, we now expect to surpass a $400 million revenue run rate during Q3, several months ahead of our original year-end target.
But we’re not just growing our top line — we’re strengthening our bottom line. Our strategy is focused on building a scalable, high-margin business model, and our recent launches of IQ2Call.ai and the upcoming AI-powered cybersecurity services through Cycurion are driving exactly that. These tech offerings are not only innovative — they are designed to increase both Net Income and Adjusted EBITDA, paving the way for sustainable, profitable growth.
To learn more about our revenue growth and projected run rate, click here.
Globetopper Acquisition – Strengthening Our Fintech Business
On July 1st, we completed the acquisition of Globetopper, a move that adds $60–70 million in annual revenue with positive EBITDA. This acquisition also plays a key role in relaunching our fintech division.
We are actively working on a plan to grow Globetopper’s revenue to $100 million annually, with at least $1 million in EBITDA, further reinforcing our leadership in global telecom and fintech services. We are planning to reach a 400M run rate in Q3, with a revenue mix of 80% telecom and 20% fintech.
To learn more about the Acquisition of GlobeTopper, click here.
We are proud to be the subject of a new independent analyst report by Hills Research, which initiated coverage on IQSTEL with a price target range of $18 to $22 per share.
This endorsement came after extensive due diligence, including in-person meetings at our Florida office and deep analysis of our technology platform. This report reflects growing institutional awareness and validation of our strategy and value proposition.
In July, we launched IQ2Call.ai, our AI-powered call center platform featuring real-time voice AI, multilingual support, and adaptive scalability with zero wait times. IQ2Call targets the $750 billion global call center industry, delivering unmatched performance and compliance.
This is a transformative milestone in our vertical integration strategy. In both Spain and the U.S., IQ2Call is already being deployed, and we’re currently closing deals that will accelerate adoption further.
To learn more information about our new product IQ2Call, click here.
Additionally, through our partnership with Cycurion, we’re also preparing to enter the cybersecurity sector, delivering new era of AI-driven cybersecurity services tailored for the telecom industry. Thanks to our deep, long-standing relationships with hundreds of global telecom operators, we will be able to cross-sell these offerings and maximize return per customer.
To learn more information about our partnership with Cycurion, click here.
Strengthening Our Balance Sheet – A Healthier, Leaner IQSTEL
We recently reduced our debt by $6.9 million, converting part into common shares and the remainder into preferred equity — all of which is already reflected in our capital structure.
This means we’ve effectively eliminated around $2 of debt per share, creating significant shareholder value. These actions also reflect investor confidence in our long-term vision to become a $1 billion revenue company by 2027.
To learn more about our debt reduction, click here
Investor Access and Institutional Outreach
In early July, we released a comprehensive investor presentation outlining our strategy, business model, financials, and future vision. We are starting actively presenting to institutional investors and family offices, encouraging them to acquire and hold IQST shares directly on the open market — with no dilution involved.
From just $13 million in 2018 to nearly $300 million in 2024, our story has been one of strategic growth and bold execution.
Now, with a healthy balance sheet, a scalable telecom and fintech platform, and a pipeline of high-tech, high-margin products, we are well on our way to:
Achieving our $340 million 2025 revenue forecast
Exceeding a $400 million run rate in Q3
Ultimately reaching $1 billion in annual revenue by
Driving sustained growth in Net Income and Adjusted EBITDA
And this is just the beginning.
With your continued trust and support, IQSTEL is writing the next chapter in technology-driven telecom innovation — and you’re part of it.
Sincerely,
Leandro Jose IglesiasPresident & CEOIQSTEL Inc. (Nasdaq: IQST)
— IQSTEL Inc. (NASDAQ: IQST) (@IQstel) May 23, 2025
IQST – IQSTEL Strengthens Equity Position with $6.9 Million Debt Cut — Almost $2 Per Share
Published
Jul 9, 2025 8:30am EDT
NEW YORK, July 9, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a leading global telecommunications and technology company, is pleased to announce a significant reduction of $6.9 million in debt from its balance sheet, marking a strategic milestone in the company’s ongoing financial strengthening and long-term growth plan.
This debt reduction will have a direct and positive impact on the company’s net stockholders’ equity, which stood at $11.34 million as of Q1 2025. The reduction was achieved through a combination of debt conversions into common shares and Series D Preferred Shares. The conversion into Series D Preferred Shares reflects investor confidence in IQSTEL’s strategic plan to reach $1 billion in annual revenue by 2027.
In addition to improving the company’s capital structure, this transaction provides $0.92 million in interest savings, directly enhancing IQSTEL’s cash flow and operational flexibility.
“Our company is $6.9 million stronger than it was last week — that’s a significant step,” said Leandro Iglesias, CEO of IQSTEL. “We are fully committed to reaching our $1 billion revenue target by 2027, and actions like this reinforce our foundation and demonstrate our determination to build long-term shareholder value. A simple and clear way to see the impact of this move is that we’ve reduced our debt by approximately $2 per share. That’s a direct and tangible creation of value for our shareholders.”
At the same time, IQSTEL is actively working on improving its adjusted EBITDA while reinforcing its balance sheet — a dual approach that the company believes is the most effective path to maximize shareholder value.
The execution date of the debt reduction was July 3, 2025, and the financial impact will be reflected in the company’s Q3 2025 Form 10-Q filing. Further details have been disclosed in the company’s corresponding Form 8-K filed with the SEC.
With these developments, IQSTEL begins the second half of 2025 on a remarkable path — stronger, leaner, and more prepared than ever to deliver on its ambitious vision.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THREE THOUSAND USD BY CORPORATE ADS LLC FOR A ONE DAY IQST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Blue Gold Limited to Acquire 90% Stake in Mampon Gold-Copper Mine, Unlocking Significant Resource Potential in Ghana
BGL is the first public company on Nasdaq tying physical gold assets to a blockchain-based token and digital wallet.
________________________
Hello Everyone,
August is off to a great start for us here. We have profiled a few high flyers and fast movers this Summer and we have a company that just started trading on the Nasdaq back in June. It has come down quite a bit since then but it appears to be stabilizing at these levels and we want you to put this on your radar for a bounce from these levels.
Pull up BGL right away.
Obviously we have not brought this one to your attention yet.
With gold reaching new all time high this year and actively retesting them, the public demand is growing. We saw this with Bitcoin. As it moved up and news highs were made, the hysteria followed.
Owning physical gold as an investment has become trendy. How do we know this? Just take a look at what Costco did.
During the summer of 2023, Costco made the move to start selling one-ounce gold bars at its wholesale locations. The rollout had been so successful that in 2024, the company added silver coins and platinum bars for sale. The gold bars have been selling out since the first introduced them and are generating revenues of between $100M and $200M MONTHLY according to Wells Fargo.
It doesn’t get more “retail” and mainstream America than Costco.
Enter BGL:
Blue Gold Limited is not just another gold miner. They’re building a digital financial ecosystem around real gold production. This is the first public company on Nasdaq tying physical gold assets to a blockchain-based token and digital wallet.
BGL gives you exposure to real, high-grade gold through a NASDAQ-listed stock while also building a blockchain-powered, gold-backed token system that lets you own future gold production straight from your phone.
If you want to own gold, let’s take a look at the options. We already know that physical gold is illiquid and inconvenient. ETFs charge fees and don’t offer true ownership and crypto isn’t backed by anything tangible generally.
As we head towards the new digital age, demand for cryptocurrency will be driven not by Generation X but a new class of individuals: Millennials. YES, MILLENNIALS! Millennials are now the largest generation in the US labor force and are expected to overtake baby boomers in population by 2019.
A 2018 survey of 2,000 people across the UK found out that millennials are more trusting of tech giants (e.g Amazon and Paypal) than they are of banks.
BGL is Where Gold Meets Fintech
BGL is launching the Blue Gold Token which is a gold-backed digital wallet tied to production. You can own fractional future gold straight from the mine and have it right on your debit card or wallet, and eventually a tokenized ecosystem.
The cornerstone asset is the Bogoso Prestea Gold Mine, located in Ghana’s Ashanti Gold Belt—one of the most prolific gold-producing regions in the world. Since 1912, over 9 million ounces of gold have been produced from the site.
Now, with over $500 million in legacy infrastructure and 5.1Moz of measured and indicated resources, Blue Gold is restarting this Tier-1 asset with a 2025 production target.
Blue Gold Limited to Acquire 90% Stake in Mampon Gold-Copper Mine, Unlocking Significant Resource Potential in Ghana
New York, New York–(Newsfile Corp. – July 30, 2025) – Blue Gold Limited (NASDAQ: BGL), a leading gold mining and resource development company, today announced it has entered into a non-binding term sheet to acquire a 90% interest in the Mampon Gold-Copper Mine in Ghana, marking a strategic expansion of its operations in the Ashanti Gold Belt.
Under the proposed agreement, Blue Gold will issue approximately US $26.25 million in equity (valued at $35 per share) to secure its majority stake. In addition, the deal includes an innovative resource-linked earn-out structure: up to US $45 per confirmed ounce of gold (capped at 6 million ounces) and US $55 per confirmed ton of copper (capped at 4 million tons).
Located just 80 kilometers north of Bogoso, the Mampon Mine is positioned for fast-track integration into Blue Gold’s existing infrastructure. The proximity to the company’s Bogoso-Prestea Mine and carbon-in-leach processing plant presents a unique opportunity to maximize efficiency and minimize capital expenditure.
An independent technical review estimates that the Mampon Mine currently holds approximately 300,000 ounces of Measured & Indicated gold resources, with substantial exploration upside.
“This acquisition aligns perfectly with our strategy to consolidate high-potential assets within reach of our existing operations,” said a spokesperson for Blue Gold. “It strengthens our footprint in Ghana while laying the groundwork for our long-term vision of delivering gold-backed digital financial solutions.”
The deal supports Blue Gold’s broader ambition to become the world’s first fully digital gold company, leveraging its physical gold reserves to back a secure digital wallet and forthcoming Blue Gold Token (BGT).
The transaction remains subject to further due diligence, final documentation, and regulatory approvals. There is no guarantee the acquisition will be completed or finalized on the current terms.
This announcement follows Blue Gold’s July 2024 acquisition of the 5.1-million-ounce Bogoso-Prestea asset, reinforcing its commitment to building one of the most dynamic portfolios in the global gold sector.
Blue Gold Limited Updates Shareholders on Strategic Growth and Vision to Become the World’s First Digital Gold Company
Blue Gold continues to execute its growth strategy by focusing on high-quality, high-margin gold and copper assets:
Strategic Pipeline: Blue Gold is actively evaluating accretive acquisition opportunities targeting 2 million ounces of annual production within five years and providing geographic diversification, underscoring its commitment to building a multi-asset, multi-jurisdictional gold producer.
Mampon Copper/Gold License Acquisition: The Company has signed its first non-binding term sheet to acquire the Mampon Copper/Gold mining license in Ghana, located approximately 80 km north of its Bogoso and Prestea mines. The acquisition structure allocates the cost of further drilling and feasibility studies to the seller, with payment contingent upon verification of resources by independent experts. Under the current terms, Blue Gold’s payment is capped at no more than $45 per oz and 6 million ounces of gold where the grade is greater than 3g/t and no more than $55 per ton and 4 million tons of copper where the grade is greater than 2%, ensuring a low-risk, high-return expansion opportunity. This is in addition to the initial consideration of $26.25m, at a $35 share price, for what the seller estimates to be 300,000 oz of Measured and Indicated Gold Resource.
Proactive Resolution of Bogoso Prestea Dispute: The Company continues to engage constructively with the Government of Ghana to resolve the lease dispute concerning the Bogoso Prestea mine, whilst also pressing ahead with the already initiated international arbitration.
DIGITAL GOLD: FROM MINE TO WALLET
Blue Gold is advancing its digital transformation strategy to create non-dilutive, technology-driven funding solutions and consumer products:
Blue Gold Token (BGT): In partnership with TripleBolt Technology, Blue Gold is investigating the creation of a BGT, a fractional gold futures token enabling individuals to acquire future gold production at competitive rates. This initiative has the potential to unlock new capital streams, reduce reliance on equity or debt, and create a transparent, asset-backed digital ecosystem.
Integrated Payments Vision: The Company is also exploring a digital gold wallet and payment platform to enable customers to hold and spend gold through everyday transactions. By pairing BGT with a gold-backed debit card, Blue Gold aims to become the world’s first “mine-to-wallet” digital gold company, merging hard-asset security with fintech innovation.
Upcoming White Paper: A comprehensive white paper on the BGT project and its potential impact on Blue Gold’s business model will be released in 2025.
“Blue Gold is evolving into a diversified gold platform that merges the physical strength of mining assets with the scalability of digital finance,” said Andrew Cavaghan, Chief Executive Officer of Blue Gold Limited. “While we continue to work towards resolving the Bogoso Prestea matter, our focus remains on growth, innovation, and delivering long-term value for our shareholders. The Mampon opportunity and the development of BGT will be key milestones in our journey to redefine what a modern gold company can be. Blue Gold remains steadfast in executing its vision of becoming a next-generation gold leader by combining strong operational performance with digital innovation.”
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND SIX HUNDRED TWENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY BGL AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Today’s profile almost broke 3 dollars and closed up double digits near the high of the day.
We have a company that just started trading on the Nasdaq.
It went absolutely nuts on the 28th when it dropped some significant news you can read down below. It ran up over 12 dollars on almost 2 BILLION in interest. You can see that it has settled down and found support in the 7 range. The story is too good to be ignored.
VisionWave is at the forefront of technological innovation, delivering cutting-edge solutions that reshape industries and set new standards for the future. Specializing in research, development, and commercialization, we combine expertise in Artificial Intelligence, aerospace engineering, Radio Frequency technology, 3D semiconductors, robotics, mesh networking, computer vision, and cybersecurity to address the world’s most complex challenges. Our core specialty lies in AI-powered technologies that transform defense capabilities and autonomous systems.
VisionWave’s combat-proven solutions are designed to enhance security, enable multi-domain operations, and drive innovation in defense and homeland security. Leveraging AI and computer vision-powered operating systems, we connect intelligent devices and hardware assets, ensuring seamless integration for maximum operational efficiency. Our advanced hardware and software applications provide real-time surveillance enhancements across air, land, and sea.
Their team excels in sectors critical to modern defense, including autonomous systems, advanced imaging, high-resolution radar, RF sensing, remote weapon systems, and micro-mobility platforms. With over 50 granted patents and a proven track record of success in commercial, medical, space, aerospace, and defense applications, VisionWave delivers combat-ready solutions that provide security awareness, multi-domain launch capabilities, and survey, inspection, and intelligence solutions across diverse environments.
VisionWave Technologies is committed to pushing the boundaries of defense technology, driving the future of innovation, and ensuring performance and reliability in the most demanding conditions.
VisionWave Secures Strategic $50 Million Equity Line to Accelerate AI-Driven Defense Platform
Published
Jul 28, 2025 8:30am EDT
WEST HOLLYWOOD, Calif., July 28, 2025 /PRNewswire/ — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a next-generation defense technology company, today announced that it has entered into a transformative funding agreement with a prominent institutional investor, securing an equity line for up to $50 million in capital through a Standby Equity Purchase Agreement (SEPA), along with a $5 million tranche funding commitment in the form of convertible notes.
This financing empowers VisionWave to execute on the strategic initiatives outlined in its investor presentation including the scaled deployment of its AI-powered multi-domain defense solutions across autonomous aerial, ground, and maritime systems.
Under the terms of the agreement, VisionWave has the right to sell up to $50 million in common stock over a 24-month period at its discretion, providing flexible, growth-focused capital. The investor also committed to funding $5 million through convertible notes to support immediate scaling efforts, of which, the first $3 million was funded upon entering into the funding agreement.
Importantly, the $5 million tranche funding includes protective covenants which prohibit the use of proceeds to pay any pre-existing liabilities accrued before the Company’s business combination. This ensures that all capital raised is strictly designated for working capital and growth initiatives, reinforcing VisionWave’s forward-focused strategy.
Noam Kenig, Chief Executive Officer of VisionWave, stated:
“This funding commitment is more than just capital — it is a validation of our business model, our mission, and the extraordinary work our team has accomplished. With this support, we are positioned to accelerate delivery on our promises, enter new markets, and deepen engagements with defense and homeland security partners globally.”
Douglas Davis, Chairman of VisionWave, added:
“Our business combination and public listing laid the foundation. This financing is the fuel. It provides us with the financial strength to scale operations, deliver cutting-edge technologies, and move faster than ever toward becoming a leader in intelligent defense systems. We viewed this investment as a mission to support national security innovation at a critical moment in time”
The proceeds from this financing will be used for working capital, product deployment, and continued innovation across VisionWave’s defense technology platforms.
ARTIFICIAL INTELLIGENCE
With extensive experience and a portfolio of globally approved patents, VisionWave is a leader in AI-driven solutions for defense, military, and law enforcement. Our proprietary AI engine powers a wide range of applications, from enhancing image quality for surveillance and intelligence to managing autonomous vehicles and remote weapon control systems.
When it comes to unmanned & remote weapon systems, VisionWave’s AI plays a pivotal role in managing both aerial and ground-based autonomous vehicles & weapons. By automating navigation, threat detection, and mission execution, our technology allows these vehicles & weapons to operate with high levels of precision and reliability in complex, high-risk environments. This reduces human exposure to danger while improving the effectiveness of missions, whether for military operations, disaster response or law enforcement.
In the realm of image enhancement and restoration, VisionWave’s AI engine enables the transformation of low-quality, incomplete visual data, & different sensing signals into clear, actionable images that provide insights. Whether used for surveillance, reconnaissance, or intelligence gathering, this capability allows operators to work with enhanced visual fidelity, even in low-light or obscured environments, ensuring critical details are captured and understood
VisionWave stays at the forefront of AI innovation by continuously monitoring advancements and developing cutting-edge technologies that shape the future of defense and security, ensuring our solutions are ready to meet both current and emerging challenges.
SENSING TECHNOLOGIES
VisionWave’s multi-patented Vision-RF system revolutionizes RF signal transformation, converting signals into real-time video for groundbreaking applications such as underground and behind-wall detection, aerial threat identification, and medical imaging.This innovative technology sets new industry standards, expanding the possibilities for real-time Vision-RF-based solutions.Our proprietary, cost-effective high-resolution radar technology, combined with super-resolution AI algorithms, delivers LIDAR-like outputs with unmatched precision and compactness.When integrated with our event-based imaging technology, these solutions are ideal for autonomous vehicles, remote weapon systems, Active Protection Systems (APS), and security applications. With a robust patent portfolio, VisionWave offers custom, cost-effective sensing solutions that ensure reliability and accuracy, even in the most challenging environments.
UNMANNED VEHICLES
VisionWave Technologies is home to a team of experts and combat-proven platforms used worldwide in unmanned systems, specifically designed for military and homeland security applications where long endurance and sensitive data collection are required.We offer a range of AI-powered autonomous platforms for air, ground, and sea, engineered to excel in the toughest conditions.Combining our proprietary sensing technologies, VisionWave’s unmanned vehicles consistently outperform competitors, driving the future of autonomous systems.
TACTICAL PLATFORMS
VisionWave redefines mobility with our micro-ATV platform, specifically designed for robust environments required by homeland security and military applications.Drawing on years of experience in the field, we have created one of the most unique platforms on the market. Featuring high maneuverability and a four-wheel-drive system, it outperforms other solutions by offering quiet, stealthy mobility—ideal for tactical special forces, law enforcement, and rapid medical deployments.The durability and silent drive of the micro-ATV provide significant advantages over gas-powered alternatives, making it a crucial asset for specialized missions where fast ground mobility is required.
Management
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND TWO HUNDRED FIFTY USD BY SHORE THING MEDIA LLC FOR A ONE DAY VWAV AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
For Monday we want to take a look at 2025’s unicorn. This is the one company that should stand out among all the others that we have profiled because of the tremendous ride it took us on earlier this year.
It is no secret to anyone that FMST went parabolic and got in front of a huge audience this year. The triple digit move generated a strong shareholder base and put the company on the radar of a lot of people that otherwise would have never heard of Foremost and what they have going on.
We brought you FMST at .96 on May first and that was just about the last time this one traded under a dollar. I’d say May was a pretty solid month for FMST. It said good night to the dollar level and ran 4.34 in under a month. Then on the 29th we said take a look at FMST again. I think we hit the jackpot that day because it was the only day it was red in 11 sessions. It pulled back to 3.30. It was green the next 5 sessions and hit 5.70.
Right now FMST is less than half of those highs it saw before it took off like a meteor. It is not often we run across a company that has the capability to move like this.
We want you to research FMST again right here at JUST 2.44 and there are several reasons as to why this needs to be on your screen again moving forward.
We need to put FMST back on the menu and not because of the parabolic move that it just made earlier this year that we were out in front of. While that is important and cannot be overlooked, there are countless other reasons as to why you are going to want to research FMST before the open.
A surge in artificial intelligence (AI) is transforming the demand for energy, with data centers powering AI applications requiring massive, round-the-clock electricity—far exceeding what traditional grid solutions can sustainably provide.
Nuclear energy has emerged as a key answer to this challenge, offering a reliable and emission-free power source perfectly suited for meeting the unprecedented needs of advanced computing infrastructure.
Prized for its high energy density and ability to deliver consistent, large-scale output, Nuclear is fueled by uranium. New, significant discoveries are imperative to keep pace with the accelerating demands of the digital economy impacting the future supply uranium supply dynamics.
The market dynamics are simple: AI doesn’t simply just run on code. It runs on URANIUM.
With 2.25 million shares traded over one day just last week—surging over 10% on Nasdaq, all eyes are laser-focused on FMST. This isn’t just looking like momentum; it looks like validation. Weathering volatility with a bullish technical backdrop as AI’s insatiable power demand collides with grid fragility, uranium is emerging as potentially the only scalable lifeline—FMST is positioning itself strategically in this critical race, drawing fierce market attention.
With a low float of approximately 9.35 million shares Foremost’s structure is engineered for explosive moves. Last week’s 10% surge on 2.25M volume proved it: this micro-float transforms supply shocks and uranium news into immediate volatility.
With over 31 countries expanding nuclear power as supply pressures build and on May 23, 2025 Trump announced 4 executive orders declaring nuclear energy security a top priority, FMST’s Athabasca Basin projects look like it has become a potentially strategic gold mine.
First and foremost, these orders will include things like:
● $2.7B in Gov’t Backing, Ban on Russian Uranium,
● Fast-Tracked Reactors including quadrupling U.S. capacity to 400 GW by 2050—requiring 2.5x more uranium than today’s entire global supply!
This isn’t just policy—it’s a potential uranium demand shock
Foremost holds 45 claims across 332,378 acres, surrounding some of the world’s largest and highest-grade uranium operations like Cigar Lake and McArthur River.
And thanks to a solid partnership with a billion-dollar cap leading uranium developer and producer, Denison Mines Corp., FMST now controls 10 prime properties in Canada’s Athabasca Basin – one of the only jurisdictions on Earth where uranium grades can regularly hit 10 – 100X higher than the global average.The region— is justifiably described as the “Saudi Arabia of Uranium”.
While others scramble, Foremost Clean Energy (NASDAQ: FMST) is already actively exploring to secure resources in Canada—a stable, democratic jurisdiction the U.S. can turn to, to evade geopolitical tensions and any global shortages that may occur, and possible price spikes.
With its low-cost, high-grade assets in the Athabasca Basin, Foremost is uniquely positioned. They could be the next uranium company to address the coming market demands while insulating American utilities from potential price spikes and supply disruptions.
Now before I look at the investor’s presentation, it’s important to put some context on what’s going on in the nuclear energy sector right now.
Uranium prices rose for 5+ years, peaking above $100 in January 2024 before hitting an 18-month low, now rebounding at $70/lb (Aug 2, 2025). President Trump’s new executive orders are revitalizing US nuclear energy and are a game changer for uranium explorers like FMST. These include, reinvigorating the nuclear industrial base, ordering the reform of the nuclear energy commission, reforming nuclear reactor testing at the Department of Energy, and deploying advanced nuclear reactor technologies for national security.
This isn’t just a small policy change. It’s unleashing a potential uranium demand tsunami. And with the US relying on Canada for approximately 25% of its uranium. We should only expect that number to skyrocket from here. Meaning that Foremost Clean Energy’s Athabasca basin projects are looking like a “strategic gold mine”.
Their 10-property portfolio sits in the same proven geological corridor as Cameco’s McArthur River—one of the richest uranium mines ever discovered.
This is not just a small market rally. This is a generational shift. Trump’s orders will quadruple US capacity to 400 gigawatt by 2050, requiring 2.5 times more uranium than today’s entire global supply. The Defense Production Act now treats uranium as national security infrastructure, prioritizing contracts with allies like Canada that supply the US with so much uranium.
Foremost is going big in 2025. Their $6.5 million exploration program is the largest among NASDAQ Athabasca uranium juniors.
With the Hatchet Lake Drill Program first phase of drilling wrapped up, what we do know, confirms what early indicators suggested – anomalous radioactivity detected in 6 out of 10 drill holes—attention now shifts to the eagerly anticipated assay results!
For those new to uranium exploration, finding ANY uranium on your first drilling attempt is like winning the lottery on your first ticket.
Finding high-grade uranium? That’s hitting the MEGA MILLIONS multi-billion jackpot!
WHAT MAKES THIS SO EXTRAORDINARY:
All within a 15m-wide alteration zone — a strong sign of a robust mineralized system
Uranium found above and below the unconformity. That’s GOOD!
A new mineralized zone discovered, extending the known strike by 50 metres
Early-stage uranium plays rarely produce results this strong, this early. This isn’t just promising … This is a completely NEW area of uranium mineralization DISCOVERY!
While others are still hunting for targets, FMST is already intercepting mineralization.. They are in the exact right place at the exact right time. Looking at the recent investors presentation, FMST is rapidly growing. HERE
Foremost isn’t just another explorer. It’s a well-capitalized drill ready opportunity in a sector set to explode with a game-changing partnership with Denison Mines.
The collaboration with Denison Mines is significant. FMST’s deal with Denison makes it one of the rarest of rare junior explorers. They aren’t just a partner but they are their largest shareholder owning approximately 16.3% of FMST’s outstanding shares and even has Denison’s CEO and President on their Board.
And Denison Mines had done years of prior exploration on this portfolio, including drilling and geophysical surveys. Foremost was not starting from scratch like other juniors.
Think about how important this can be. Unlike most junior explorers focused on single targets, FMST is diversified across 10 separate properties each with multiple drill ready zones. This dramatically increases the odds of a major discovery. It also enables Foremost to launch multiple exploration campaigns simultaneously, something that very few of its peers can do, putting Foremost at the forefront of a market set to explode.
With Denison Mine’s extensive historical work already done, Foremost Clean Energy (NASDAQ: FMST) provided a clear roadmap to high-priority targets —giving it an edge most early-stage explorers simply didn’t have.
Some of Foremost’s properties can be found alongside or within major uranium trends including the LaRocque corridor – host to IsoEnergy’s world-class Hurricane Deposit (48.6M lbs at 34.5% U3O8), underscoring the high-grade discovery potential of Foremost’s projects.
Foremost’s Properties surrounded by High-grade deposits, Mines and Mills
The company is positioned to capitalize on the uranium market renaissance with over 31 nations pledging to triple nuclear capacity by 2050. This is a projected period of sustained structural uranium supply shortages. There is also secondary lithium upside for this company with five Canadian lithium projects spanning 55,000 acres with long-term development potential.
With Denison already mining and preparing to launch Canada’s first ISR uranium mine by 2028, FMST is perfectly aligned to benefit from that first mover advantage.This suggests that if Foremost discovers a uranium deposit, they already have a partner capable of refining and delivering it to a supply starved market..
Canada already supplies around 25% of US uranium needs. This relationship is so essential that even the Trump administration has limited tariffs on uranium to only 10% demonstrating its energy importance.
The uranium market outlook is bullish and the small modular reactor market (SMR’s) is expected to expand to over 8 billion by 2028. These SMRs are considered to be the future of nuclear power and some of the world’s largest companies are switching to these in order to power their data centers.The SMRs are advanced nuclear reactors that have a power capacity of up to 300 MW(e) per unit, which is about one-third of the generating capacity of traditional nuclear power reactors. SMRs can produce a large amount of low-carbon electricity, and their systems and components can be factory-assembled and transported as a unit for installation.
AI’s energy needs are giving FMST the opportunity of a lifetime. WHY?
Tech giants are scrambling to find reliable sources of energy:
Meta just bought 1.1 gigawatts of reactor power—enough to light up a million AI servers.
Amazon locked down 1,920 megawatts for its AWS data fortresses; Google’s bidding war for uranium contracts is raging in the shadows.
In May, Google signed an agreement with a nuclear developer for three 600-megawatt advanced reactors.
On June 3, the Wall Street Journal reported that “Meta Signs Nuclear Power Deal to Fuel Its AI Ambitions.”
on June 20, 2025, SPUT- Sprott Physical Uranium Trust – announced a $200M bought deal to acquire physical uranium—the entire sector is feeling the tightening supply even further in an already strained market. With SPUT hoarding physical uranium, high-grade explorers in the Athabasca Basin like FMST find themselves extremely well positioned!
In July 2025, Westinghouse just announced a $75 Billion plan to build 10 nuclear reactors — each powering 750,000 homes — using their AP1000 design.
These reactors will support $90B in energy/AI infrastructure projects also announced.
This means that Foremost is perfectly positioned in the right place at the right time to take advantage, drilling the Athabasca basin just as uranium’s supply crisis hits.
The world demand for nuclear power looks set to skyrocket, demanding more uranium than ever. Foremost Energy’s deal with Denison Mines looks like it could be a gamechanger.
Foremost Clean Energy Announces Drilling at its Murphy Lake South Uranium Project
VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”), is pleased to announce that drilling is scheduled to begin this month at the Murphy Lake South Uranium Property (“Murphy”), which is located in the world-renowned Athabasca Basin region of northern Saskatchewan. This fully permitted and fully funded program is designed as a first phase of multiple potential phases, intended to test high-priority structural corridors adjacent to the renowned LaRocque Lake Conductive Corridor—host to IsoEnergy’s Hurricane Deposit, one of the highest-grade uranium discoveries in the world.
Murphy’s proximity to this corridor places it within a highly prospective structural environment, where recent exploration success has dramatically shifted perceptions of the area’s potential. The Hurricane discovery underscored the significance of graphitic fault systems and basement-rooted structures in the Mudjatik Domain, long overlooked in favor of the eastern Athabasca’s more celebrated Wollaston Domain.
Jason Barnard, President and CEO of Foremost, commented: “For years, uranium explorers focused their attention on the Wollaston Domain, and rightly so— as it produced giants like McArthur River, Cigar Lake, and Key Lake. Meanwhile, the Mudjatik Domain was considered a second-tier target, despite its deep structural complexity and close proximity to infrastructure. That mindset changed with IsoEnergy’s Hurricane discovery, which proved that world-class deposits can—and do—exist within the Mudjatik. At Murphy, we’re excited to be drilling a project with strong historical intercepts, relatively shallow unconformity depths, and clear signs of a mineralized hydrothermal system. Given its adjacency to the LaRocque Corridor and the presence of offset structures, graphitic units, and pathfinder element anomalies, we believe Murphy represents one of the best exploration opportunities in our portfolio of projects.”
The Murphy Lake South Property, covers 17,676 acres approximately 30 kilometers northwest of the McClean Lake mll and has been the focus of multiple historical drill campaigns by Denison Mines between 2008 and 2017. These programs identified uranium mineralization and key alteration features, including:
0.25% U₃O₈ over 6 meters (MP-15-031)
0.13% U₃O₈ over 12.5 meters just above the unconformity (MP-16-112)
0.03% U₃O₈ over 22.5 meters from 255 to 277.5 meters (MP-16-173)
Associated pathfinder elements such as nickel, cobalt, and boron1
Figure 1. Foremost Clean Energy Projects in Regional Context
Phase 1 drilling, is expected to begin later in July, and is planned to consist of approximately 1,500 meters of diamond drilling focused on graphitic faults and offset structures identified through past geophysics and geological interpretation. These targets are located within 200–350 meters of surface, offering an efficient test of the unconformity and underlying basement rocks. A Phase 2 winter program is contemplated to follow up on successful results and test additional conductive trends.
Murphy exhibits the essential hallmarks of an Athabasca unconformity-style system, including structural complexity, alteration, offset basement wedges, and conductive graphitic packages—all in a region that remains significantly underexplored.
Qualified Person
The technical content of this news release has been reviewed and approved by Cameron MacKay, P. Geo., Vice President of Exploration for Foremost Clean Energy Ltd., and a Qualified Person under National Instrument 43-101, who has prepared and reviewed the content of this press release.
A qualified person has not performed sufficient work or data verification to validate the historical results in accordance with National Instrument 43-101. Although the historical results may not be reliable, the Company nevertheless believes that they provide an indication of the property’s potential and are relevant for any future exploration program.
Foremost Clean Energy Exercises Low-Cost Option to Acquire 100% Ownership of Jean Lake Lithium-Gold Property
By completing this option agreement first entered into in July 2021, Foremost has acquired 100% interest in the Jean Lake Lithium-Gold Property with historic high-grade gold intercepts and confirmed lithium mineralization
VANCOUVER, British Columbia, July 16, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company“), is pleased to announce it has exercised a low-cost option to acquire a 100% interest in the 2,476-acre Jean Lake Lithium-Gold Project (“Jean Lake”) in Manitoba’s Snow Lake District. The Company finalized ownership by making a final cash payment of $75,000 and issuing $75,000 worth of common shares to Mount Morgan Resources Ltd. (“Mount Morgan”), purchasing the property for a total of $250,000 cash, issuing a total aggregate of 47,299 of the Company’s common shares, and incurring the required exploration expenditures. Mount Morgan retains a 2% Net Smelter Royalty (“NSR”), with the Company retaining the right to repurchase 1% for $1,000,000.
Key Highlights
Foremost Safeguards Value With Established Potential: Jean Lake is a prospective Gold and Lithium exploration property where Foremost’s initial drill program intercepted 7.50 g/t Au over 7.66m (including 102.0 g/t Au over 0.48 metres) in drill hole FM23-8 and 1.26% Li₂O over 3.35m in drill hole FM23-04A.
Strategic Infrastructure: The property is within close proximity to power access, highway, rail, airstrip and mines, making it ideally situated for future advancement as a gold and/or lithium development project.
Proven Jurisdiction: Located in proximity to Hudbay Minerals’ core operating area, which has produced more than 1 million+ ounces of gold at its Lalor Mine1.
Foremost’s President and CEO, Jason Barnard comments, “Prior to Foremost’s pivot to focus on uranium exploration in the prolific Athabasca Basin region of northern Saskatchewan, Foremost invested successfully in lithium and gold exploration in Manitoba – generating positive results and confirming the prospectivity of the Company’s Manitoba project portfolio. With gold achieving historic price highs, our Jean Lake property provides exceptional leverage and optionality with its demonstrated high-grade gold mineralization and confirmation of lithium mineralization. With a modest final investment in the property, Foremost has successfully secured this prospective asset.”
Mr. Barnard continues, “Amidst our operational update, our deepest solidarity remains with the people of the Snow Lake region during this devastating wildfire season. The mandatory evacuation orders impacting families, First Nations partners, and our dedicated local workforce underscore the profound human dimension of this crisis. We recognize the resilience shown by this community, one that has supported Manitoba’s mining legacy for generations, and extend our unwavering commitment to their safety and recovery, and recognize the efforts of emergency responders to protect those impacted by the wildfires.”
Foremost’s 2022/2023 Drill Campaign
The Company completed a 3,002 metre initial diamond drill program, designed to test targets based on integrated prospecting, UAV-borne magnetic survey results, MMI soil geochemical surveys and outcrop rock chip analyses (Foremost news release June 6, 2023). The program intersected numerous gold mineralized intervals at vertical depths up to 110 m below surface as well as lithium at the B1 spodumene bearing pegmatite. The locations of drill holes that intersected gold mineralized intervals are illustrated in Figure 1, in addition to the B1 drill hole location. Details of the lithium and gold intersections are provided in Table 1 below.
Highlights include:
GOLD
In drill hole FM23-8: 7.50 g/t Au over 7.66 metres from 94.35 – 102.01 m (including 102.0 g/t Au over 0.48 metres from 94.77 – 95.25 m)
In drill hole FM23-04A: 11.27 g/t Au over 2.75 metres from 73.75 – 76.50 m (including 91.8 g/t Au over 0.32 metres from 74.74 – 75.06 m)
In drill hole FM23-01A: 2.46 g/t Au over 3.70 metres from 41.30 – 45.00m
LITHIUM
1.26% Li2O over 3.35 metres in drill hole FM23-01A
Figure 1. Lithium and Gold Intersections Drill Holes
Table 1 – 2022 – 2023 Program Lithium and Gold Intersections in Drill Holes
Hole IDEastingNorthingStrikeDipDepthIntercept in MetresFM23-01A 452688 6076420 205 -66 62m 1.26% Li2O over 0-3.35mFM23-01A 452688 6076420 205 -66 62 2.46 g/t Au over 3.70m from 41.30m-45mFM23-04A 452743 6076529 90 -45 80 11.27 g/t Au over 2.75m from 73.75m-76.5m including 91.8 g/t Au over 0.32mfrom 74.74 – 75.06mFM23-08 452877 6076534 245 -45 134 1.44 g/t Au for 0.32m from 11.33m-11.65m and 7.50 g/t Au for 7.66m from 94.35m-102.01m including 29.95 g/t Au for 1.77m from 94.35m-96.12m and 1.28 g/t Au for 0.3m from 107.6m-107.9mFM23-08A 452878 6076543 110 -45 173 1.51 g/t Au for 0.52m from 95.18m-95.7mFM23-13 452667 6076898 270 -45 125 0.94 g/t Au for 1.23m from 121.30m-122.53mFM23-14 452732 6076854 270 -45 158 1.23 g/t Au for 2.85m from 151.24m-154.09mFM23-22 450367 6073940 314 -45 125 3.04 g/t Au for 0.68m from 102.92m-103.6mFM23-25 452347 6076330 120 -45 114 2.07 g/t Au for 3.49m from 25.3m-28.79m including 6.86 g/t Au for 0.54m from 25.30m-25.84m and 1.27 g/t Au for 2.4m from 69.6m-72m
2025 Jean Lake Planned Drill Program
Foremost plans to conduct a 15-hole, 2,500-metre diamond drill program at Jean Lake before the end of this year to satisfy the Company’s commitments. Targets include the B-1 spodumene bearing pegmatite dyke along strike towards the B-2 and B-3 pegmatites extending the mineralization laterally.
Potential for additional gold mineralization at depth will be targeted based on encouraging results from previous completed drill program. Of interest is the occurrence of 2.46 g/t Au over 3.70m from 41.30m-45m in DHFM23-01A. This intersection occurs in a shear zone at or near the base of the B1 pegmatite in fine grained gabbro. Gold is associated with quartz veins and arsenopyrite.
Gold
Previous drill testing in 2023 of integrated geological and geochemical targets elsewhere on the Jean Lake intersected numerous gold mineralized intervals at vertical depths of up to 110 metres below surface. Highlights from this program included 7.50 g/t Au over 7.66 metres from 94.35 – 102.01 metres (including 102.0 g/t Au over 0.48 metres from 94.77 – 95.25 metres). Further investigation and drilling will assess the potential for additional gold mineralization at depth as well as create a geological framework to aid in delineating gold intersected during the 2022-23 drill program.
History of Gold in the Jean Lake Property Area
Historically, 5.5 million ounces of gold has been produced as a by-product of base metal copper-zinc massive sulphide type deposit production, in addition to major gold deposits such as the New Britannia, Puffy Lake, and Tartan deposits with cumulative production of more than 1.5 million ounces of gold, in the Flin Flon-Snow Lake greenstone belt2. In 1940, two bulk samples from the Jean Lake Property (then known as the Sparky Gold Property), weighing 22.7 and 22.2 kg. respectively, were sent to the Canada Department of Mines and Resources in Ottawa for testing3. The first bulk sample contained 16.46 g/t gold and 2.39 g/t silver, and the second bulk sample contained 241.71 g/t gold and 12.34 g/t silver. Gold exploration continued unabated in the area with high-grade gold mineralization documented from numerous past producing gold mines and properties hosting significant gold mineralization.
Lithium
It is the Company’s goal to develop a better understanding of the spodumene-bearing pegmatite emplacement mechanisms at Jean Lake. Foremost’s drill program, combined with field observations, have indicated that B-1 and B-2 could be one spodumene-bearing pegmatite with a minimum length of 325 metres. Previous drilling, just north of the B1 pegmatite outcrop, intersected a 3.35 metre zone of spodumene mineralization between surface and 3.35 metres, assaying 1.26% Li2O. The program also aims to assess whether the B-1 pegmatite is part of a larger lithium pegmatite cluster near Snow Lake Energy’s lithium deposits, which could significantly enhance the region’s lithium resource potential (see figure 2).
Figure 2. Map of Jean Lake’s B1, B2 and B3 Spodumene Bearing Pegmatites
Wildfire Impact and Mitigation
Active wildfires in northern Manitoba prompted evacuation orders in Snow Lake, temporarily suspending regional mining operations.4 Hudbay Minerals Inc., a major operator in Snow Lake, re-opened the Lalor Mine in 2022, has secured its facilities and expects minimal impact on its 2025 gold production guidance of 190,000+ ounces5. Foremost will advance further planning in preparation for its 15-hole 2,500 metre diamond hole drill program to commence once authorities declare safe conditions.
Qualified Person
Technical information in this news release has been reviewed and approved by Lindsay Bottomer, P.Geo., who is a Qualified Person as defined by Canadian National Instrument 43-101-Standards of Disclosure for Mineral Projects.
CEO And President, And Non-Independent Executive Board Member
Jason Barnard
Mr. Barnard has over 31 years of capital markets experience. Since 2004, he has been self-employed as a private investor where he has been directly involved in raising over $500 million dollars for mining and exploration companies with a focused expertise on Canadian base metal companies.
Mr. Barnard started his career with McDermid St. Laurence Securities in 1991 as a stockbroker with primary focus in mining, and mining exploration companies. Mr. Barnard then worked at Canaccord Genuity from 1997 until 2004. Mr. Barnard holds a Bachelor of Arts degree with a major in Economics from Carlton University and has obtained The Canadian Securities Course license in 1990. He first started working with and financing Foremost Lithium, previously known as Far Resources, with founder, and President Keith Anderson in 2016 and is the Company’s largest shareholder.
David Cates
Independent Director
David Cates
Mr. Cates is a Chartered Professional Accountant (CPA, CA) and holds Master of Accounting (MAcc) and Honours Bachelor of Arts (BA) degrees from the University of Waterloo. Mr. Cates has extensive expertise in the Canadian and international uranium mining industry from over a decade of senior management and financial experience in various roles with Denison.
Mr. Cates was appointed President & CEO of Denison in 2015, having previously served as the company’s Vice President, Finance & Tax and Chief Financial Officer. Prior to joining Denison in 2008, Mr. Cates held positions at Kinross Gold Corp. and PwC LLP. Mr. Cates also serves as a Director of the Canadian Nuclear Association and of SkyHarbour Resources Ltd.
JODY DAHROUGE, B.SC., SP.C., – P. GEOL.
Geological Advisor
Jody Dahrouge
Mr. Dahrouge has been the President of Dahrouge Geological Consulting Ltd., a North American mineral exploration, consulting, and project management group, since 1988. He is a professional geologist with over 30 years’ experience and holds Bachelor of Science degrees in geology and computing science, both from the University of Alberta.
Mr. Dahrouge has been involved in all aspects of mineral exploration and development for a wide variety of commodities worldwide. Dahrouge Geological Consulting Ltd. has been instrumental in a multitude of grassroots discoveries across a wide variety of commodities and currently has boots on the ground on multiple Canadian and American projects
MARK FEDIKOW PH.D. P.GEO. CPG
Geoscientific Advisor
Mark Fedikow
Dr. Fedikow has over 40 years of experience as an exploration geochemist and a mineral deposits geologist working in both private and public sectors. He is a Fellow at the Association of Applied Geochemists, where he’s previously worked as a councilor. Dr. Fedikow has also served on numerous industry-related committees. He also pioneered the application of regional multimedia geochemical and mineralogical surveys in support of base and precious metal and diamond exploration in Manitoba.
During his 45-year career he has worked for a variety of junior and major mining exploration and mining companies and for the Manitoba Geological Survey as Chief Geologist of the Mineral Deposits Section. In 2001 he received the Provincial Geologists gold medal, a Canadian national award for excellence in the geosciences.
In 2002 Mark left the Manitoba Geological Survey to start his own company (Mount Morgan Resources Ltd.) providing consulting services to the metal and hydrocarbon exploration industry. He is currently registered as P.Eng. and P.Geo. with Engineers Geoscientists Manitoba (“EGM”), P.Geo. with the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists (NAPEG) and as a Certified Professional Geologist (C.P.G.) with the American Institute of Professional Geologists (“A.I.P.G.”), Westminster, Colorado, U.S.A.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THREE THOUSAND ONE HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY FMST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Nanoviricides, Inc. is close to having a single drug NV-387 for the treatment of all of the “tripledemic” respiratory viruses – Coronaviruses, RSV, and Influenza A, which would be a revolutionary achievement! NNVC has closed Green 11 out of the last 15
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate
We havre something back on our our list for tomorrow’s session that has been familiar to our members over the past few months. This one has been moving and is sitting about 30-40 cents higher than the last time we profiled it.
Pull up NNVC ahead of tomorrow’s session.
Take a look at the chart below. This is one. is approaching the 52 week high……… in fact, in anothe month or so these levels would be the 52 week high.
It has closed green 11 of the last 15 sessions and is sitting right at resistance.
We really want to emphasize the need to research NNVC right here.
NNVC looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NNVC is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.
NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.
Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..
Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
NV-387 – A novel broad-spectrum antiviral
Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments???????????
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!
Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa – Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NV-387 – Phase II Clinical Trial to Treat MPox Infection – Unmet Medical Need
We reported that we submitted requisite due diligence information to the National Ethics Committee of the Democratic Republic of Congo (DRC) including a draft report from the Phase I clinical trial for the safety and tolerability of oral formulations of NV-387, the summary information from our studies for treatment of lethal MPox infections in animal models, as well as summary information on the manufacturing.
The National Ethics Committee found that the provided information was sufficient to justify a Phase II clinical trial, and has cleared us to file a Phase II Clinical Trial Application for the Use of Oral NV-387 for the Treatment of MPox Disease Caused by the hMPXV virus, subsequent to the reporting period.
We also reported that we have commissioned manufacture of clinical trial quantities of NV-387 drug substance and the corresponding NV-387 oral gummies formulations drug products at our own cGMP compliant facility in Shelton, CT.
We are now preparing the Phase II Clinical Trial Application for NV-387 to combat MPOX for submission to the DRC regulatory agency.
There is no drug available for the treatment of MPox disease. The MPox Clade 1a/1b viruses have a substantially greater fatality rate than COVID, at 3-4%, and Clade 1b has been disproportionately affecting pediatric populations.
The MPox Disease which is caused by hMPXV Clade 1a/1b virus infection was initially declared a Public Health Emergency of International Concern (PHEIC) by the WHO in August 2024, a designation that has been continued to stay in effect in April 2025, due to the severity of the pandemic in WHO African Region.
Spillover cases of MPox Clade 1a/1b have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as Coronaviruses or Measles virus.
MPox Clade 2 spilled over from Africa into the Western World in a small pandemic during 2022, and has become endemic with several cases occurring every year in many countries, driven primarily by sexual contact. MPox Clade 2 causes much less severe disease than the Clade 1a and 1b viruses.
MPox/Smallpox drug represents a billion dollar market globally, should an effective drug be developed, because of potential biosecurity implications.
NV-387 as Treatment for Measles Virus Infection – Unmet Medical Need
Upon finding significant rationale that NV-387 would be potentially highly effective against the Measles virus, we have initiated a program to evaluate NV-387 in a humanized animal model of Measles lethal infection.
The Measles outbreaks in the USA have continued to grow since January, 2025, and have crossed 1,000 confirmed cases as well as 3 deaths. Measles cases have been increasing year over year in the USA, especially after the COVID pandemic substantially resolved with the SARS-CoV-2 becoming an endemic virus. In Europe, over 35,000 cases of Measles have been reported in 2024 according to the European CDC.
A 95% vaccination coverage is required to eliminate Measles virus. This has become a practically impossible goal because of several factors, among them: (i) Vaccine Hesitancy as a rebound public response because of compulsion of COVID vaccine shots multiple times; (ii) Religious Vaccine Prohibitions in certain communities, including certain Jewish religious communities, Mennonites, and other conservative religious communities; (iii) Increasing immune function disability in the general population due to chronic diseases such as Diabetes, Obesity, Cardiac Issues, Autoimmune Diseases, Allergies, etc. wherein the person upon vaccination would not develop strong enough immunity and would become a carrier if infected; (iv) Vaccine Failure caused primarily by a variety of immune function disabilities.
The Measles vaccination rates across the world, and particularly in European countries and the USA have dipped well below 95% on average, and much lower in specific areas, and vaccine breakout cases i.e. Measles disease in vaccinated persons, have also increased substantially, as seen from the ECDC statistics [1] , [2] .
It is therefore essential to develop a drug to treat Measles in order to combat these outbreaks and achieve full control over the public health situation. There is no drug available for treatment of Measles.
We strongly expect that NV-387 would be effective against Measles. This is because NV-387 cured lethal RSV infection in an animal model. RSV and Measles both are paramyxoviruses, and both use HSPG as the Attachment Receptor, and then transfer to their respective Cognate Receptor that is needed for cell fusion. NV-387 was designed to present to the virus like a cell that displays HSPG-mimetic small chemical ligands on its surface, thereby providing the attachment-receptor-mimetic landing sites for the virus, capturing, engulfing, and destroying it. (HSPG = Heparan Sulfated Proteoglycans).
NV-387 as Treatment for Bird Flu, H5N1, H7N9 – Unmet Medical Need
We have previously found that NV-387 was substantially more effective than the existing stockpiled influenza virus treatments including Tamiflu (oseltamivir) and Xofluza (baloxavir) in lethal animal models of Influenza virus lung infection.
Given the extremely broad antiviral activity spectrum of NV-387, and knowing that the Highly Pathogenic Avian Influenza (HPAI) viruses such as H5N1 and H7N9 have polybasic sequences in their H-protein that bind to HSPG, we believe NV-387 would be effective against Bird Flu viruses.
Influenza viruses mutate rapidly, and also exchange their full genomic RNA segments with other co-infecting viruses (“Re-assortment”), or copy portions of a different genomic sequence into their own RNA (“Re-combination”). Thereby an Influenza virus can acquire new traits such as (i) rapid communicability from person-to-person, and (ii) readily escaping vaccines, antibodies, and the small chemical drugs such as oseltamivir and baloxavir.
NV-387, we believe, fulfills the unmet medical need for a pan-Influenza drug that the Influenza virus would not be able to escape, because the virus does not lose its ability bind to HSPG as Attachment Receptor and then to Sialic Acid Receptors leading to cell fusion and infection.
A severe version of H5N1 is widely circulating in the wild birds, and has caused sporadic losses of entire poultry farm houses. This, and a mild version of H5N1 have infected thousands of dairy herds in the USA. The H5N1 virus is only a few mutations away from becoming highly communicable from person to person, and if that comes to bear, we would be facing a pandemic possibly worse than COVID-19.
It is well established now that vaccines, antibodies, and small chemical drugs do not provide the ability to stall an outbreak let alone a pandemic caused by a highly variable virus such as a Coronavirus or an Influenza virus.
We believe NV-387 will be ready to fight any human outbreaks of H5N1 under emergency use protocols for investigational drugs.
Company Financials
We reported that, as of March 31, 2025, we had cash and cash equivalent current assets balance of approximately $2.73 Million. In addition, we reported approximately $6.98 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.20 Million.
The net cash utilized during the nine months ended March 31, 2025 was approximately $6.78 million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase IIclinical trial application. We raised approximately $4.57 million net of commission and certain expenses in an At-the-Market offering (“ATM”) during the nine months ended March 31, 2025.
We have approximately $5.7 million (approximately $4.5 million net of current liabilities) available for cash operational expenses going forward including an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. As such, we reported that we do not have sufficient funding in hand to continue operations through February 14, 2026, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPOX in Central Africa, (ii) a Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI), and (iii) Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA. We have access to the aforementioned ATM Equity Offering, and we believe we will have access to the equity markets to raise the funds necessary for our current objectives. We continue to re-prioritize our programs in line with available resources.
NV-387 – Phase I Clinical Trial Completed Successfully with No Reported Adverse Events
NV-387 has successfully completed a Phase Ia/Ib clinical trial in healthy subjects with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial.
NV-387 A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape
Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, Influenza, and Mpox/Smallpox.
In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.
NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche).
Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with or superior to the approved drug tecovirimat (TPOXX®, SIGA).
NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for COVID, Influenza and Poxviruses.
This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.
Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.
Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.
NV-387 Regulatory Strategy
In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. In addition to the Phase II clinical trial to assess effectiveness of NV-387 in treating MPox infections, we are also planning to advance NV-387 into a Phase II clinical trial for treatment of Viral Acute Respiratory Infections (V-ARI), and Viral Severe Acute Respiratory Infections (V-SARI). This clinical trial is expected to provide information on NV-387 effectiveness in treating Influenza viruses, Coronaviruses (including SARS-CoV-2/COVID) as well as RSV.
Thereafter we are planning a regulatory program for advancing NV-387 as the treatment of pediatric RSV infection.
We plan on advancing the regulatory processes for NV-387 registration for other indications including Influenza and COVID via partnerships and non-dilutive funding.
As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides’ Dr. Diwan
PUBLISHED
JUN 18, 2025 6:30AM EDT
SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.
Nimbus causes “razor-sharp” sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.
Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.
Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.
Recently, the Influenza A H5N1 virus from a dairy worker in Michiganwas found to be capable of airborne transmission in a ferret animal model [1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.
NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.
NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.
Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.
NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.
COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.
NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.
NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.
NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.
“NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “We have US-based cGMP manufacturing capabilities already set up as well.”
Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.
Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).
Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.
The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”) today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared for further regulatory filing of a complete Clinical Trial Application (“CTA”).
“We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of MPOX disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company.
The Company previously announced in January, 2025 that it has engaged a CRO for conducting a Phase II clinical trial to evaluate the safety and effectiveness of NV-387 for the treatment of MPox in the African Region.
Subsequently, the CRO has engaged the Medical Hospital at the University of Kinshasa as the clinical trial site (the “Site”) for the Phase II clinical trial.
Thereafter, the Company, the CRO, and the Principal Investigator at the Site have developed a package of information comprising synopses of the clinical trial protocol, and required background information on the novel drug NV-387, including a draft summary report of the Phase I human clinical trial, prior non-clinical data, as well as summary of the animal model effectiveness and safety of NV-387 for the treatment of lethal MPox infection providing rationale for the use of the novel broad-spectrum antiviral drug NV-387 for the treatment of hMPXV viral infection and the MPox disease caused by the infection.
This summary package was submitted to the National Regulatory Agency’s Ethics Committee CNES for a first review towards approval to proceed to the preparation and submission of the detailed CTA to the National Regulatory Agency, namely MSP of DRC.
The approval that we have now received from CNES clears the path for the perfected CTA filing to the MSP for approval and start of the clinical trial.
There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024.
“NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”
NV-387 was found to be highly effective in increasing survival in lethal animal models of influenza virus, surpassing existing drugs Tamiflu®, Rapivab® and Xofluza® by a large margin.
NV-387 led to a complete cure of lethal RSV lung infection in an animal model study. There is no approved drug for RSV treatment.
NV-387 was found to be highly effective in increasing survival in lethal animal models of Coronavirus infection (a stand-in model for SARS-CoV-2 infection), surpassing existing drug remdesivir by a large margin.
NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.
In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.
Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.
Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.
In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.
MPox disease, caused by the human MPox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the WHO African Region that includs the Democratic Republic of Congo (DRC), Uganda, and other countries. It led to the WHOdeclaring a Public Health Emergency of International Concern (“PHEIC”) on August 14, 2024. Since then, the PHEIC status declaration has been extended twice, most recently in March, 2025. The Mpox epidemic has continued to spread in the DRC, Uganda, and neighboring countries and the number of new weekly cases is still increasing in the WHO African Region.
NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.
Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.
New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND TWENTY FIVE USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
